Document:

Exhibit 4.1

 

WARRANT AGREEMENT

 

between

 

MEDICUS SCIENCES ACQUISITION CORP.

 

and

 

CONTINENTAL STOCK TRANSFER & TRUST COMPANY

 

Dated February 15, 2021

 

THIS WARRANT AGREEMENT (this “Agreement”),
dated February 15, 2021, is by and between Medicus Sciences Acquisition Corp., a Cayman Islands exempted company (the “Company”),
and Continental Stock Transfer & Trust Company, a New York limited purpose trust company, as warrant agent (in such capacity,
the “Warrant Agent”).

 

WHEREAS, the Company is engaged in an initial
public offering (the “Offering”) of units of the Company’s equity securities (the “Units”)
for purposes of financing its initial business combination through a merger, share exchange, asset acquisition, share purchase,
reorganization or similar business combination, involving the Company and one or more businesses (the “Business Combination”);

 

WHEREAS, the Units to be sold in the Offering
will be comprised of one Class A ordinary share, par value $0.0001 per share (the “Ordinary Shares”),
one-ninth of one redeemable warrant (the “Outstanding Redeemable Warrants”) and a contingent right to
receive at least two-ninths of one redeemable warrant (the “Distributable Redeemable Warrants” and, collectively
with the Outstanding Redeemable Warrants, the “Redeemable Warrants”) following the time at which the
Company redeems the Ordinary Shares that the holders thereof have elected to redeem in connection with the Business Combination
(the “Distribution Time”). Each whole Redeemable Warrant entitles the holder thereof to purchase one
Ordinary Share for $11.50 per share, subject to adjustment as described herein. Only whole Warrants are exercisable. A holder of
the Redeemable Warrants will not be able to exercise any fraction of a Redeemable Warrant;

 

WHEREAS, the Company has determined to
issue and deliver in the Offering 8,000,000 (or up to 9,200,000 if the Over-allotment Option (as defined below) is exercised in
full) Ordinary Shares and 888,889 (or up to 1,022,222, if the Over-allotment Option is exercised in full) Outstanding Redeemable
Warrants to public investors in the Offering;

 

WHEREAS, the Company has filed with the
Securities and Exchange Commission (the “Commission”) a registration statement on Form S-1, File No.
333-251674 (the “Registration Statement”), and a prospectus (the “Prospectus”),
for the registration, under the Securities Act of 1933, as amended (the “Securities Act”), of the Units,
including the Ordinary Shares included in the Units, the Outstanding Redeemable Warrants and the contingent rights to receive the
Distributable Redeemable Warrants; and

 

WHEREAS, on February 15, 2021, the Company
entered into that certain Private Placement Warrants Purchase Agreement with Medicus Sciences Holdings LLC, a Delaware limited
liability company (the “Sponsor”), pursuant to which the Sponsor agreed to purchase an aggregate of 3,555,556
warrants (or up to 3,642,222 warrants if the underwriters in the Offering exercise their Over-allotment Option in full) simultaneously
with the closing of the Offering (and the closing of the Over-allotment Option, if applicable), bearing the legend set forth in
Exhibit B hereto (the “Sponsor Private Placement Warrants”), at a purchase price of $0.90 per
Sponsor Private Placement Warrant and in connection therewith, will issue and deliver up to 3,642,222 Sponsor Private Placement
Warrants; and

 

WHEREAS, on February 15, 2021, the
Company entered into that certain Private Placement Warrants Purchase Agreement with Maxim Partners LLC
(“Maxim”), pursuant to which Maxim agreed to purchase an aggregate of 1,200,000 warrants (or up to
1,380,000 warrants if the underwriters in the Offering exercise their Over-allotment Option in full) simultaneously with the
closing of the Offering (and the closing of the Over-allotment Option, if applicable), bearing the legend set forth in Exhibit
C hereto (the “Maxim Private Placement Warrants” and, together with the Sponsor Private
Placement Warrants, the “Private Placement Warrants” and, together with the Redeemable Warrants and
the Forward Purchase Warrants, the “Warrants”) at a purchase price of $0.90 per Maxim Private
Placement Warrant and in connection therewith, will issue and deliver up to 1,380,000 Maxim Private Placement Warrants. Each
Private Placement Warrant entitles the holder thereof to purchase one Ordinary Share at a price of $11.50 per share, subject
to adjustment as described herein; and

 

    1 

     

    

 

WHEREAS, on February 15, 2021, the Company
entered into that certain Forward Purchase Agreement (the “Forward Purchase Agreement”) with Altium MSAC,
LLC, a Delaware limited liability company, and Structure Alpha LLC, a Delaware limited liability company (collectively, the “Forward
Purchasers”), pursuant to which each of the Forward Purchasers agreed to purchase units (the “Forward
Purchase Units”) for a maximum aggregate purchase price of $16,000,000, with each Forward Purchase Unit having a
purchase price of $10.00 and consisting of one Ordinary Share (the “Forward Purchase Shares”), and one-third
of one warrant bearing the legend set forth in Exhibit D hereto (the “Forward Purchase Warrants”
and together with the Ordinary Shares issuable upon the exercise thereof, the Forward Purchase Units and the Forward Purchase Shares,
the “Forward Purchase Securities”) in one or more private placement transactions to occur in such amounts
and at such time or times as the Forward Purchasers determine, but no later than simultaneously with the closing of the Company’s
initial Business Combination;

 

WHEREAS, on February 15, 2021, the Company
entered into that certain Registration Rights Agreement (the “Registration Rights Agreement”), with the
Sponsor, Maxim, the Forward Purchasers and other parties named therein, providing for the registration for resale of certain securities
held by the parties thereto;

 

WHEREAS, the Company desires the Warrant
Agent to act on behalf of the Company, and the Warrant Agent is willing to so act, in connection with the issuance, registration,
transfer, exchange, redemption and exercise of the Warrants; and

 

WHEREAS, the Company desires to provide
for the form and provisions of the Warrants, the terms upon which they shall be issued and exercised, and the respective rights,
limitation of rights and immunities of the Company, the Warrant Agent and the holders of the Warrants; and

 

WHEREAS, all acts and things have been
done and performed which are necessary to make the Warrants, when executed on behalf of the Company and countersigned by or on
behalf of the Warrant Agent (if a physical certificate is issued), as provided herein, the valid, binding and legal obligations
of the Company, and to authorize the execution and delivery of this Agreement.

 

NOW, THEREFORE, in consideration of the
mutual agreements herein contained, the parties hereto agree as follows:

 

1. Appointment of Warrant Agent.
The Company hereby appoints the Warrant Agent to act as agent for the Company for the Warrants, and the Warrant Agent hereby accepts
such appointment and agrees to perform the same in accordance with the terms and conditions set forth in this Agreement.

 

2. Warrants.

 

2.1. Form of Warrant. Each Warrant
shall initially be issued in registered form only.

 

2.2. Effect of Countersignature.
If a physical certificate is issued, unless and until countersigned by the Warrant Agent pursuant to this Agreement, a certificated
Warrant shall be invalid and of no effect and may not be exercised by the holder thereof.

 

2.3. Registration.

 

2.3.1. Warrant Register. The Warrant
Agent shall maintain books (the “Warrant Register”), for the registration of original issuance and the
registration of transfer of the Warrants. Upon the initial issuance of the Warrants in book-entry form, the Warrant Agent shall
issue and register the Warrants in the names of the respective holders thereof in such denominations and otherwise in accordance
with instructions delivered to the Warrant Agent by the Company. Ownership of beneficial interests in the Redeemable Warrants shall
be shown on, and the transfer of such ownership shall be effected through, records maintained by institutions that have accounts
with The Depository Trust Company (the “Depositary”) (such institution, with respect to a Warrant in
its account, a “Participant”).

 

    2 

     

    

 

If the Depositary subsequently ceases to
make its book-entry settlement system available for the Redeemable Warrants, the Company may instruct the Warrant Agent regarding
making other arrangements for book-entry settlement. In the event that the Redeemable Warrants are not eligible for, or it is no
longer necessary to have the Redeemable Warrants available in, book-entry form, the Warrant Agent shall provide written instructions
to the Depositary to deliver to the Warrant Agent for cancellation each book-entry Redeemable Warrant, and the Company shall instruct
the Warrant Agent to deliver to the Depositary definitive certificates in physical form evidencing such Warrants (“Definitive
Warrant Certificates”) which shall be in the form annexed hereto as Exhibit A.

 

Physical certificates, if issued, shall
be signed by, or bear the facsimile signature of, the Chairman of the Board, Chief Executive Officer, President, Chief Financial
Officer, Chief Operating Officer, General Counsel, Secretary or other principal officer of the Company. In the event the person
whose facsimile signature has been placed upon any Warrant shall have ceased to serve in the capacity in which such person signed
the Warrant before such Warrant is issued, it may be issued with the same effect as if he or she had not ceased to be such at the
date of issuance.

 

2.3.2. Registered Holder. Prior
to due presentment for registration of transfer of any Warrant, the Company and the Warrant Agent may deem and treat the person
in whose name such Warrant is registered in the Warrant Register (the “Registered Holder”) as the absolute
owner of such Warrant and of each Warrant represented thereby, for the purpose of any exercise thereof, and for all other purposes,
and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary. 

 

2.4. Detachability of Outstanding Redeemable
Warrants. The Ordinary Shares and Outstanding Redeemable Warrants comprising the Units shall begin separate trading on the
52nd day following the date of the Prospectus or, if such 52nd day is not on a day, other than a Saturday, Sunday or federal holiday,
on which banks in New York City are generally open for normal business (a “Business Day”), then on the
immediately succeeding Business Day following such date, or earlier (the “Detachment Date”) with the
consent of Maxim, as representative of the several underwriters, but in no event shall the Ordinary Shares and the Outstanding
Redeemable Warrants comprising the Units be separately traded until (A) the Company has filed (i) a Current Report on Form 8-K
with the Commission containing an audited balance sheet reflecting the receipt by the Company of the gross proceeds of the Offering,
including the proceeds then received by the Company from the exercise by the underwriters of their right to purchase additional
Units in the Offering (the “Over-allotment Option”), if the Over-allotment Option is exercised prior
to the filing of the Current Report on Form 8-K and (ii) a second or amended Current Report on Form 8-K to provide updated financial
information to reflect the exercise of the underwriters’ Over-allotment Option, if the Over-allotment Option is exercised
following the initial filing of such Current Report on Form 8-K, and (B) the Company issues a press release announcing when such
separate trading shall begin.

 

2.5 Distributable Redeemable Warrants.
At the Distribution Time, an aggregate of 1,777,778 Distributable Redeemable Warrants will be distributed by the Company as follows:
(i) to the extent that no public holders of Ordinary Shares (such holders, “Public Shareholders”) redeem
their Ordinary Shares in connection with the Business Combination each Public Shareholder will receive two-ninths of a Distributable
Redeemable Warrant, and (ii) to the extent that any Public Shareholders redeem any of their Ordinary Shares in connection with
the Business Combination, then (A) two-ninths of a Distributable Redeemable Warrant will be issued for each Ordinary Share that
was not redeemed (the “remaining public shares”), and (B) the aggregate amount of 1,777,778 Distributable Redeemable
Warrants less the number of warrants issued pursuant to the foregoing clause (A) will be issued on a pro rata basis to the holders
of the remaining public shares based on their percentage of Ordinary Shares held after redemptions. To the extent that a Public
Shareholder redeems any of their Ordinary Shares in connection with the Business Combination, that Public Shareholder will receive
no portion of any Distributable Redeemable Warrant per Ordinary Share redeemed. The right to receive the Distributable Redeemable
Warrants is not separable from the Ordinary Shares and is not separately transferrable, assignable or salable. The Distributable
Redeemable Warrants will be issued in the same form as the Outstanding Redeemable Warrants, in book-entry form or as otherwise
provided in Section 2.3.1 hereof. Upon the issuance and distribution of the Distributable Redeemable Warrants, the Distributable
Redeemable Warrants will be fully fungible with the Outstanding Redeemable Warrants, and will begin trading on the first trading
day following the Distribution Time under the same stock symbol and CUSIP as the Outstanding Redeemable Warrants. No Distributable
Redeemable Warrants will be distributed in respect of outstanding Ordinary Shares issued pursuant to the Forward Purchase Agreement
or any other Ordinary Shares that were not issued in the Offering.

 

    3 

     

    

 

2.6. Fractional Warrants. The Company
shall not issue fractional Warrants other than as part of the Units or the Forward Purchase Units. If, upon the detachment of the
Outstanding Redeemable Warrants from the Units, the issuance of the Distributable Redeemable Warrants or otherwise, a holder of
Warrants would be entitled to receive a fractional Warrant, the Company shall round down to the nearest whole number the number
of Redeemable Warrants to be issued to such holder. A fractional Forward Purchase Warrant may be transferred, assigned or sold
only as a part of a Forward Purchase Unit. If, as a result of (i) the purchase of the Forward Purchase Units or (ii) any transfer,
assignment or sale of Forward Purchase Units, a Forward Purchaser or such transferee becomes the holder of a fractional Forward
Purchase Warrant, such holder will not be permitted to exercise such fractional Forward Purchase Warrant. Only whole Warrants may
be exercised.

 

2.7. Private Placement Warrants.

 

2.7.1 The Private Placement
Warrants shall be identical to the Redeemable Warrants, except that so long as they are held by the Sponsor, Maxim, or any of their
Permitted Transferees (as defined below), the Private Placement Warrants: (i) may be exercised for cash or on a “cashless
basis,” pursuant to subsection 3.3.1(b) hereof, (ii) including the Ordinary Shares issuable upon exercise of the Private
Placement Warrants, may not be transferred, assigned or sold until thirty (30) days after the completion by the Company of an initial
Business Combination and (iii) shall not be redeemable by the Company pursuant to Section 6.1 hereof; provided, however,
that in the case of (ii), the Private Placement Warrants and any Ordinary Shares issued upon exercise of the Private Placement
Warrants held by the Sponsor, Maxim, or any of their Permitted Transferees (as defined below) may be transferred by the holders
thereof:

 

(a) to the Company’s or Maxim’s
officers or directors, any affiliates or family members of any of the Company’s or Maxim’s officers or directors, any
members or partners of the Sponsor, Maxim or their affiliates, any affiliates or the Sponsor or Maxim or any employees of such
affiliates;

 

(b) in the case of an individual, by gift
to a member of one of the individual’s immediate family or to a trust, the beneficiary of which is a member of the individual’s
immediate family, an affiliate of such person or to a charitable organization;

 

(c) in the case of an individual, by virtue
of laws of descent and distribution upon death of the individual;

 

(d) in the case of an individual, pursuant
to a qualified domestic relations order;

 

(e) by private sales or transfers made
in connection with the consummation of a Business Combination at prices no greater than the price at which the Private Placement
Warrants or Ordinary Shares, as applicable, were originally purchased;

 

(f) by virtue of the Sponsor’s or
Maxim’s organizational documents upon liquidation or dissolution of the Sponsor or Maxim;

 

(g) to the Company for no value for cancellation
in connection with the consummation of the Company’s initial Business Combination;

 

(h) in the event of the Company’s
liquidation prior to the completion of its initial Business Combination; or

 

(i) in the event of the Company’s
completion of a liquidation, merger, share exchange or other similar transaction which results in all of the Public Shareholders
having the right to exchange their Ordinary Shares for cash, securities or other property subsequent to the completion of the Company’s
initial Business Combination;

 

provided, however,
that, in the case of clauses (a) through (f), these permitted transferees (the “Permitted
Transferees”) must enter into a written agreement with the Company agreeing to be bound by these transfer
restrictions and the other restrictions in t the letter agreement, dated as of the date hereof, by and among the Company, the
Sponsor and the Company’s directors and officers and by the same agreements entered into by the Sponsor with respect to
such securities (including provisions relating to voting, the trust account and liquidation distributions described elsewhere
in the Prospectus). Notwithstanding the foregoing, with respect to any Private Placement Warrants held by Maxim and/or its
designees, in addition to the foregoing restriction on transfer of the Private Placement Warrants, the Private Placement
Warrants purchased by Maxim and/or its designees shall not be sold during the Offering, or sold, transferred, assigned,
pledged or hypothecated for a period of 180 days immediately following the date of effectiveness of the Registration
Statement or commencement of sales of the Offering, except to any member participating in the Offering and the officers or
partners thereof. Additionally, the Private Placement Warrants purchased by Maxim and/or its designees shall not be the
subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic
disposition of the securities by any person for a period of 180 days immediately following the date of effectiveness of the
Registration Statement or commencement of sales of the Offering.

 

    4 

     

    

 

2.8 Forward Purchase Warrants. The
Forward Purchase Warrants shall be subject to the transfer restrictions set forth in this Agreement and the Forward Purchase Agreement,
and shall have registration rights as set forth in the Registration Rights Agreement. Upon the earlier of (i) the effectiveness
of a registration statement covering the resale of the Forward Purchase Warrants and Ordinary Shares issuable upon the exercise
thereof or (ii) the date on which all of the Forward Purchase Warrants and the Ordinary Shares stock issuable upon the exercise
thereof can be publicly sold without restriction or limitation under Rule 144 of the Securities Act, the Forward Purchase Warrants
will become fully fungible with the Redeemable Warrants, and will have the same CUSIP number and be tradable under the same stock
symbol as the Redeemable Warrants. Except as otherwise provided in this Agreement, the Forward Purchase Agreement (with respect
to certain transfer restrictions) and the Registration Rights Agreement (with respect to certain registration rights), as applicable,
the Forward Purchase Warrants, once issued, will be identical to the Redeemable Warrants in all respects.

 

2.8.1 Transfer Restrictions on Forward
Purchase Securities. As provided in the Forward Purchase Agreement, the Forward Purchase Securities may not be transferred,
assigned or sold until the completion of the Business Combination, except (i) to any affiliate transferee or (ii) in the event
of the Company’s liquidation prior to the completion of the Business Combination; provided, however, that any such permitted
transferee must enter into a written agreement agreeing to be bound by the same transfer restrictions and the other restrictions
contained in the Forward Purchase Agreement with respect to the Forward Purchase Securities and by the same agreements entered
into by the Forward Purchasers with respect to the Forward Purchase Securities. The Forward Purchase Shares and the Forward Purchase
Warrants shall not be separately transferable until the completion of the Business Combination.

 

3. Terms and Exercise of Warrants.

 

3.1. Warrant Price. Each whole Warrant
shall entitle the Registered Holder thereof, subject to the provisions of such Warrant and of this Agreement, to purchase from
the Company the number of Ordinary Shares stated therein, at the price of $11.50 per share, subject to the adjustments provided
in Section 4 hereof and in the last sentence of this Section 3.1. The term “Warrant Price”
as used in this Agreement shall mean the price per share (including in cash or by payment of Warrants pursuant to a “cashless
exercise,” to the extent permitted hereunder) described in the prior sentence at which Ordinary Shares may be purchased at
the time a Warrant is exercised. The Company in its sole discretion may lower the Warrant Price at any time prior to the Expiration
Date (as defined below) for a period of not less than fifteen Business Days (unless otherwise required by the Commission, any national
securities exchange on which the Warrants are listed or applicable law); provided that the Company shall provide at least three
Business Days’ prior written notice of such reduction to Registered Holders of the Warrants; and provided further, that any
such reduction shall be identical among all of the Warrants.

 

3.2. Duration of Warrants. A
Warrant may be exercised only during the period (the “Exercise Period”) (A) commencing on the later
of: (i) the date that is thirty (30) days after the completion of the initial Business Combination, and (ii) the date that is
twelve (12) months from the date of the closing of the Offering, and (B) terminating at the earliest to occur of (x) 5:00
p.m., New York City time on the date that is five (5) years after the date on which the Company completes its initial
Business Combination, (y) the liquidation of the Company in accordance with the Company’s amended and restated
memorandum and articles of association, as amended from time to time (the “Amended and Restated Memorandum and
Articles of Association”), if the Company fails to complete a Business Combination, and (z) other than with
respect to the Private Placement Warrants then held by the Sponsor, Maxim or their Permitted Transferees, 5:00 p.m., New York
city time on the Redemption Date (as defined below) as provided in Section 6.3 hereof (the “Expiration
Date”); provided, however, that the exercise of any Warrant shall be subject to the satisfaction
of any applicable conditions, as set forth in subsection 3.3.2 below, with respect to an effective registration
statement or a valid exemption therefrom being available. Except with respect to the right to receive the Redemption Price
(as defined below) (other than with respect to a Private Placement Warrant then held by the Sponsor, Maxim or their Permitted
Transferees) in the event of a redemption (as set forth in Section 6 hereof), each Warrant (other than a Private
Placement Warrant then held by the Sponsor, Maxim or their Permitted Transferees in the event of a redemption) not exercised
on or before the Expiration Date shall become void, and all rights thereunder and all rights in respect thereof under this
Agreement shall cease at 5:00 p.m. New York City time on the Expiration Date. The Company in its sole discretion may extend
the duration of the Warrants by delaying the Expiration Date; provided that the Company shall provide at least twenty
(20) days prior written notice of any such extension to Registered Holders of the Warrants and, provided further that
any such extension shall be identical in duration among all the Warrants. Notwithstanding anything to the contrary contained
herein, for so long as any Private Placement Warrant is held by Maxim and/or its designees, such Private Placement Warrant
may not be exercised after five years from the effective date of the Registration Statement.

 

    5 

     

    

 

3.3. Exercise of Warrants.

 

3.3.1. Payment. Subject to the provisions
of the Warrant and this Agreement, a Warrant may be exercised by the Registered Holder thereof by delivering to the Warrant Agent
at its corporate trust department (i) the Definitive Warrant Certificate evidencing the Warrants to be exercised, or, in the case
of a Warrant represented by a book-entry, the Warrants to be exercised (the “Book-Entry Warrants”) on
the records of the Depositary to an account of the Warrant Agent at the Depositary designated for such purposes in writing by the
Warrant Agent to the Depositary from time to time, (ii) an election to purchase (“Election to Purchase”)
any Ordinary Shares pursuant to the exercise of a Warrant, properly completed and executed by the Registered Holder on the reverse
of the Definitive Warrant Certificate or, in the case of a Book-Entry Warrant, properly delivered by the Participant in accordance
with the Depositary’s procedures, and (iii) the payment in full of the Warrant Price for each Ordinary Share as to which
the Warrant is exercised and any and all applicable taxes due in connection with the exercise of the Warrant, the exchange of the
Warrant for the Ordinary Shares and the issuance of such Ordinary Shares, as follows:

 

(a) in lawful money of the United States,
in good certified check or good bank draft payable to the order of the Warrant Agent;

 

(b) with respect to any Private Placement
Warrant, so long as such Private Placement Warrant is held by the Sponsor, Maxim, or a Permitted Transferee, by surrendering the
Warrants for that number of Ordinary Shares equal to the quotient obtained by dividing (x) the product of the number of Ordinary
Shares underlying the Warrants, multiplied by the excess of the “Fair Market Value” (as defined in this
subsection 3.3.1(b)) over the Warrant Price by (y) the Sponsor Fair Market Value. Solely for purposes of this subsection
3.3.1(b), the “Fair Market Value” shall mean the average of the daily volume-weighted average prices
of the Ordinary Shares for the ten (10) consecutive trading days ending on the trading day prior to the date on which the notice
of exercise is received by the warrant agent;

 

(c) as provided in Section 6.2 hereof
with respect to a Make-Whole Exercise; or

 

(d) as provided in Section 7.4 hereof.

 

3.3.2. Issuance of Ordinary Shares
on Exercise. As soon as practicable after the exercise of any Warrant and the clearance of the funds in payment of the
Warrant Price (if payment is pursuant to subsection 3.3.1(a)) or the surrender of Warrants in connection with a
cashless exercise, the Company shall issue to the Registered Holder of such Warrant a book-entry position or certificate, as
applicable, for the number of Ordinary Shares to which he, she or it is entitled, registered in such name or names as may be
directed by him, her or it on the register of members of the Company, and if such Warrant shall not have been exercised in
full, a new book-entry position or countersigned Warrant, as applicable, for the number of Ordinary Shares as to which such
Warrant shall not have been exercised. Notwithstanding the foregoing, the Company shall not be obligated to deliver any
Ordinary Shares pursuant to the exercise of a Warrant and shall have no obligation to settle such Warrant exercise unless a
registration statement under the Securities Act with respect to the Ordinary Shares underlying the Redeemable Warrants is
then effective and a prospectus relating thereto is current, subject to the Company’s satisfying its obligations under Section
7.4 or a valid exemption from registration is available. No Warrant shall be exercisable and the Company shall not be
obligated to issue Ordinary Shares upon exercise of a Warrant unless the Ordinary Shares issuable upon such Warrant exercise
have been registered, qualified or deemed to be exempt from registration or qualification under the securities laws of the
state of residence of the Registered Holder of the Warrants. Subject to Section 4.6 of this Agreement, a Registered
Holder of Warrants may exercise its Warrants only for a whole number of Ordinary Shares. The Company may require holders of
Redeemable Warrants to settle the Warrant on a “cashless basis” pursuant to Section 7.4. If, by reason of
any exercise of Warrants on a “cashless basis”, the holder of any Warrant would be entitled, upon the exercise of
such Warrant, to receive a fractional interest in an Ordinary Share, the Company shall round down to the nearest whole
number, the number of Ordinary Shares to be issued to such holder.

 

    6 

     

    

 

3.3.3. Valid Issuance. All Ordinary
Shares issued upon the proper exercise of a Warrant in conformity with this Agreement and the Amended and Restated Memorandum and
Articles of Association of the Company shall be validly issued, fully paid and nonassessable.

 

3.3.4. Date of Issuance. Each person
in whose name any book-entry position or certificate, as applicable, for Ordinary Shares is issued and who is registered in the
register of members of the Company shall for all purposes be deemed to have become the holder of record of such Ordinary Shares
on the date on which the Warrant, or book-entry position representing such Warrant, was surrendered and payment of the Warrant
Price was made, irrespective of the date of delivery of such certificate in the case of a certificated Warrant, except that, if
the date of such surrender and payment is a date when the register of members of the Company or book-entry system of the Warrant
Agent are closed, such person shall be deemed to have become the holder of such Ordinary Shares at the close of business on the
next succeeding date on which the share transfer books or book-entry system are open.

 

3.3.5. Maximum Percentage. A holder
of a Warrant may notify the Company in writing in the event it elects to be subject to the provisions contained in this subsection
3.3.5; however, no holder of a Warrant shall be subject to this subsection 3.3.5 unless he, she or it makes such
election. If the election is made by a holder, the Warrant Agent shall not effect the exercise of the holder’s Warrant, and
such holder shall not have the right to exercise such Warrant, to the extent that after giving effect to such exercise, such person
(together with such person’s affiliates), to the Warrant Agent’s actual knowledge, would beneficially own in excess
of 9.9% (the “Maximum Percentage”) of the Ordinary Shares outstanding immediately after giving effect
to such exercise. For purposes of the foregoing sentence, the aggregate number of Ordinary Shares beneficially owned by such person
and its affiliates shall include the number of Ordinary Shares issuable upon exercise of the Warrant with respect to which the
determination of such sentence is being made, but shall exclude Ordinary Shares that would be issuable upon (x) exercise of the
remaining, unexercised portion of the Warrant beneficially owned by such person and its affiliates and (y) exercise or conversion
of the unexercised or unconverted portion of any other securities of the Company beneficially owned by such person and its affiliates
(including, without limitation, any convertible notes or convertible preferred shares or warrants) subject to a limitation on conversion
or exercise analogous to the limitation contained herein. Except as set forth in the preceding sentence, for purposes of this paragraph,
beneficial ownership shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the
 “Exchange Act”). For purposes of determining the number of outstanding Ordinary Shares, the holder may
rely on the number of outstanding Ordinary Shares as reflected in (1) the Company’s most recent Annual Report on Form 10-K,
Quarterly Report on Form 10-Q, Current Report on Form 8-K or other public filing with the Commission as the case may be, (2) a
more recent public announcement by the Company or (3) any other notice by the Company or Continental Stock Transfer & Trust
Company, as transfer agent (in such capacity, the “Transfer Agent”), setting forth the number of Ordinary
Shares outstanding. For any reason at any time, upon the written request of the holder of the Warrant, the Company shall, within
two (2) Business Days, confirm orally and in writing to such holder the number of Ordinary Shares then outstanding. In any case,
the number of issued and outstanding Ordinary Shares shall be determined after giving effect to the conversion or exercise of equity
securities of the Company by the holder and its affiliates since the date as of which such number of issued and outstanding Ordinary
Shares was reported. By written notice to the Company, the holder of a Warrant may from time to time increase or decrease the Maximum
Percentage applicable to such holder to any other percentage specified in such notice; provided, however, that any
such increase shall not be effective until the sixty-first (61st) day after such notice is delivered to the Company.

  

4. Adjustments.

 

4.1. Share Capitalizations.

 

4.1.1. Sub-Divisions. If after
the date hereof, and subject to the provisions of Section 4.6 below, the number of issued and outstanding Ordinary
Shares is increased by a capitalization or share dividend of Ordinary Shares (other than the issuance of Ordinary Shares
pursuant to the Forward Purchase Agreement), or by a sub-division of Ordinary Shares or other similar event, then, on the
effective date of such share capitalization, sub-division or similar event, the number of Ordinary Shares issuable on
exercise of each Warrant shall be increased in proportion to such increase in the issued and outstanding Ordinary Shares. A
rights offering (other than with respect to the right of Public Shareholders to acquire the Distributable Redeemable
Warrants) made to all or substantially all holders of Ordinary Shares entitling holders to purchase Ordinary Shares at a
price less than the “Historical Fair Market Value” (as defined below) shall be deemed a share dividend of a
number of Ordinary Shares equal to the product of (i) the number of Ordinary Shares actually sold in such rights offering (or
issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for Ordinary
Shares) multiplied by (ii) one (1) minus the quotient of (x) the price per Ordinary Share paid in such rights offering
divided by (y) the Historical Fair Market Value. For purposes of this subsection 4.1.1, (i) if the rights offering is
for securities convertible into or exercisable for Ordinary Shares, in determining the price payable for Ordinary Shares,
there shall be taken into account any consideration received for such rights, as well as any additional amount payable upon
exercise or conversion and (ii) “Historical Fair Market Value” means the volume weighted average
price of the Ordinary Shares as reported during the ten (10) trading day period ending on the trading day prior to the first
date on which the Ordinary Shares trade on the applicable exchange or in the applicable market, regular way, without the
right to receive such rights. No Ordinary Shares shall be issued at less than their par value.

 

    7 

     

    

 

4.1.2. Extraordinary Dividends.
If the Company, at any time while the Warrants are outstanding and unexpired, pays a dividend or makes a distribution in cash,
securities or other assets to all or substantially all of the holders of the Ordinary Shares on account of such Ordinary Shares
(or other securities into which the Warrants are convertible), other than (a) as described in subsection 4.1.1 above, (b)
Ordinary Cash Dividends (as defined below), (c) to satisfy the redemption rights of the holders of the Ordinary Shares in connection
with a proposed initial Business Combination, (d) to satisfy the redemption rights of the holders of Ordinary Shares in connection
with a shareholder vote to amend the Amended and Restated Memorandum and Articles of Association (i) to modify the substance or
timing of the Company’s obligation to provide holders of Ordinary Shares the right to have their shares redeemed in connection
with the Company’s initial Business Combination or to redeem 100% of the Company’s public shares if it does not complete
its initial Business Combination within 24 months from the closing of the Offering or (ii) with respect to any other provision
relating to the rights of holders of Ordinary Shares or pre-initial Business Combination activity, (e) in connection with the redemption
of public shares upon the failure of the Company to complete its initial Business Combination and any subsequent distribution of
its assets upon its liquidation or (f) the issuance and distribution of the Distributable Redeemable Warrants (any such non-excluded
event being referred to herein as an “Extraordinary Dividend”), then the Warrant Price shall be decreased,
effective immediately after the effective date of such Extraordinary Dividend, by the amount of cash and/or the fair market value
(as determined by the Company’s board of directors (the “Board”), in good faith) of any securities
or other assets paid on each Ordinary Share in respect of such Extraordinary Dividend. For purposes of this subsection 4.1.2,
 “Ordinary Cash Dividends” means any cash dividend or cash distribution which, when combined on a per
share basis, with all other cash dividends and cash distributions paid on the Ordinary Shares during the 365-day period ending
on the date of declaration of such dividend or distribution does not exceed $0.50 (which amount shall be adjusted to appropriately
reflect any of the events referred to in other subsections of this Section 4 and excluding cash dividends or cash distributions
that resulted in an adjustment to the Warrant Price or to the number of Ordinary Shares issuable on exercise of each Warrant) but
only with respect to the amount of the aggregate cash dividends or cash distributions equal to or less than $0.50 per share.

 

4.2. Aggregation of Shares. If after
the date hereof, and subject to the provisions of Section 4.6 hereof, the number of issued and outstanding Ordinary Shares
is decreased by a consolidation, combination, reverse share sub-division or reclassification of Ordinary Shares or other similar
event, then, on the effective date of such consolidation, combination, reverse share sub-division, reclassification or similar
event, the number of Ordinary Shares issuable on exercise of each Warrant shall be decreased in proportion to such decrease in
issued and outstanding Ordinary Shares.

 

4.3. Adjustments in Exercise Price.
Whenever the number of Ordinary Shares purchasable upon the exercise of the Warrants is adjusted, as provided in subsection
4.1.1 or Section 4.2 above, the Warrant Price shall be adjusted (to the nearest cent) by multiplying such Warrant Price
immediately prior to such adjustment by a fraction (x) the numerator of which shall be the number of Ordinary Shares purchasable
upon the exercise of the Warrants immediately prior to such adjustment, and (y) the denominator of which shall be the number of
Ordinary Shares so purchasable immediately thereafter.

 

    8 

     

    

 

4.4. Raising of the Capital in Connection
with the Initial Business Combination. If (x) the Company issues additional Ordinary Shares or securities convertible into
or exercisable or exchangeable for Ordinary Shares for capital raising purposes in connection with the closing of its initial Business
Combination at an issue price or effective issue price of less than $9.20 per Ordinary Share (with such issue price or effective
issue price to be determined in good faith by the Board and, in the case of any such issuance to the Sponsor or its affiliates,
without taking into account any Class B ordinary shares of the Company, par value $0.0001 per share (the “Class B Ordinary
Shares”), held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly
Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity
proceeds, and interest thereon, available for the funding of the Company’s initial Business Combination on the date of the
consummation of the Company’s initial Business Combination (net of redemptions), and (z) the volume-weighted average trading
price of Ordinary Shares during the twenty (20) trading day period starting on the trading day prior to the day on which the Company
consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share,
the Warrant Price shall be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued
Price, the $18.00 per share redemption trigger price described in Section 6.1 and Section 6.2 shall be adjusted (to
the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price and the $10.00 per share redemption
trigger price described in Section 6.2 shall be adjusted (to the nearest cent) to be equal to the higher of the Market Value and
the Newly Issued Price.

 

4.5. Replacement of Securities
upon Reorganization, etc. In case of any reclassification or reorganization of the issued and outstanding Ordinary Shares
(other than a change under Section 4.1 or Section 4.2 hereof or that solely affects the par value of such
Ordinary Shares), or in the case of any merger or consolidation of the Company with or into another corporation (other than a
consolidation or merger in which the Company is the continuing corporation and that does not result in any reclassification
or reorganization of the issued and outstanding Ordinary Shares), or in the case of any sale or conveyance to another
corporation or entity of the assets or other property of the Company as an entirety or substantially as an entirety in
connection with which the Company is dissolved, the holders of the Warrants shall thereafter have the right to purchase and
receive, upon the basis and upon the terms and conditions specified in the Warrants and in lieu of the Ordinary Shares of the
Company immediately theretofore purchasable and receivable upon the exercise of the rights represented thereby, the kind and
amount of Ordinary Shares or other securities or property (including cash) receivable upon such reclassification,
reorganization, merger or consolidation, or upon a dissolution following any such sale or transfer, that the holder of the
Warrants would have received if such holder had exercised his, her or its Warrant(s) immediately prior to such event (the
 “Alternative Issuance”); provided, however, that (i) if the holders of the Ordinary
Shares were entitled to exercise a right of election as to the kind or amount of securities, cash or other assets receivable
upon such consolidation or merger, then the kind and amount of securities, cash or other assets constituting the Alternative
Issuance for which each Warrant shall become exercisable shall be deemed to be the weighted average of the kind and amount
received per share by the holders of the Ordinary Shares in such consolidation or merger that affirmatively make such
election, and (ii) if a tender, exchange or redemption offer shall have been made to and accepted by the holders of the
Ordinary Shares (other than a tender, exchange or redemption offer made by the Company in connection with redemption rights
held by shareholders of the Company as provided for in the Amended and Restated Memorandum and Articles of Association or as
a result of the repurchase of Ordinary Shares by the Company if a proposed initial Business Combination is presented to the
shareholders of the Company for approval) under circumstances in which, upon completion of such tender or exchange offer, the
maker thereof, together with members of any group (within the meaning of Rule 13d-5(b)(1) under the Exchange Act) of which
such maker is a part, and together with any affiliate or associate of such maker (within the meaning of Rule 12b-2 under the
Exchange Act) and any members of any such group of which any such affiliate or associate is a part, own beneficially (within
the meaning of Rule 13d-3 under the Exchange Act) more than 50% of the issued and outstanding Ordinary Shares, the holder of
a Warrant shall be entitled to receive as the Alternative Issuance, the highest amount of cash, securities or other property
to which such holder would actually have been entitled as a shareholder if such Warrant holder had exercised the Warrant
prior to the expiration of such tender or exchange offer, accepted such offer and all of the Ordinary Shares held by such
holder had been purchased pursuant to such tender or exchange offer, subject to adjustments (from and after the consummation
of such tender or exchange offer) as nearly equivalent as possible to the adjustments provided for in this Section 4; provided
further that if less than 70% of the consideration receivable by the holders of the Ordinary Shares in the applicable
event is payable in the form of Ordinary Shares in the successor entity that is listed for trading on a national securities
exchange or is quoted in an established over-the-counter market, or is to be so listed for trading or quoted immediately
following such event, and if the Registered Holder properly exercises the Warrant within thirty (30) days following the
public disclosure of the consummation of such applicable event by the Company pursuant to a Current Report on Form 8-K filed
with the Commission, the Warrant Price shall be reduced by an amount (in dollars) equal to the difference of (i) the Warrant
Price in effect prior to such reduction minus (ii) (A) the Per Share Consideration (as defined below) (but in no event less
than zero) minus (B) the Black-Scholes Warrant Value (as defined below). The “Black-Scholes Warrant
Value” means the value of a Warrant immediately prior to the consummation of the applicable event based on the
Black-Scholes Warrant Model for a Capped American Call on Bloomberg Financial Markets (assuming zero dividends)
(“Bloomberg”). For purposes of calculating such amount, (i) Section 6 of this Agreement
shall be taken into account, (ii) the price of each Ordinary Share shall be the volume weighted average price of the Ordinary
Shares during the ten (10) trading day period ending on the trading day prior to the effective date of the applicable event,
(iii) the assumed volatility shall be the 90 day volatility obtained from the HVT function on Bloomberg determined as of the
trading day immediately prior to the day of the announcement of the applicable event and (iv) the assumed risk-free interest
rate shall correspond to the U.S. Treasury rate for a period equal to the remaining term of the Warrant. “Per
Share Consideration” means (i) if the consideration paid to holders of the Ordinary Shares consists exclusively
of cash, the amount of such cash per Ordinary Share, and (ii) in all other cases, the volume weighted average price of the
Ordinary Shares during the ten (10) trading day period ending on the trading day prior to the effective date of the
applicable event. If any reclassification or reorganization also results in a change in Ordinary Shares covered by subsection
4.1.1, then such adjustment shall be made pursuant to subsection 4.1.1 or Sections 4.2, 4.3 and this Section
4.4. The provisions of this Section 4.4 shall similarly apply to successive reclassifications, reorganizations,
mergers or consolidations, sales or other transfers. In no event shall the Warrant Price be reduced to less than the par
value per share issuable upon exercise of such Warrant.

 

    9 

     

    

 

4.6. Notices of Changes in Warrant.
Upon every adjustment of the Warrant Price or the number of shares issuable upon exercise of a Warrant, the Company shall give
written notice thereof to the Warrant Agent, which notice shall state the Warrant Price resulting from such adjustment and the
increase or decrease, if any, in the number of Ordinary Shares purchasable at such price upon the exercise of a Warrant, setting
forth in reasonable detail the method of calculation and the facts upon which such calculation is based. Upon the occurrence of
any event specified in Sections 4.1, 4.2, 4.3, 4.4 or 4.5, the Company shall give written notice
of the occurrence of such event to each holder of a Warrant, at the last address set forth for such holder in the Warrant Register,
of the record date or the effective date of the event. Failure to give such notice, or any defect therein, shall not affect the
legality or validity of such event.

 

4.7. No Fractional Shares. Notwithstanding
any provision contained in this Agreement to the contrary, the Company shall not issue fractional Ordinary Shares upon the exercise
of Warrants. If, by reason of any adjustment made pursuant to this Section 4, the holder of any Warrant would be entitled,
upon the exercise of such Warrant, to receive a fractional interest in a share, the Company shall, upon such exercise, round down
to the nearest whole number the number of Ordinary Shares to be issued to such holder.

 

4.8. Form of Warrant. The form of
Warrant need not be changed because of any adjustment pursuant to this Section 4, and Warrants issued after such adjustment
may state the same Warrant Price and the same number of Ordinary Shares as is stated in the Warrants initially issued pursuant
to this Agreement; provided, however, that the Company may at any time in its sole discretion make any change in
the form of Warrant that the Company may deem appropriate and that does not affect the substance thereof, and any Warrant thereafter
issued or countersigned, whether in exchange or substitution for an outstanding Warrant or otherwise, may be in the form as so
changed.

 

4.9 Other Events. In case any event
shall occur affecting the Company as to which none of the provisions of the preceding subsections of this Section 4 are
strictly applicable, but which would require an adjustment to the terms of the Warrants in order to (i) avoid an adverse impact
on the Warrants and (ii) effectuate the intent and purpose of this Section 4, then, in each such case, the Company shall
appoint a firm of independent public accountants, investment banking or other appraisal firm of recognized national standing, which
shall give its opinion as to whether or not any adjustment to the rights represented by the Warrants is necessary to effectuate
the intent and purpose of this Section 4 and, if they determine that an adjustment is necessary, the terms of such adjustment.
The Company shall adjust the terms of the Warrants in a manner that is consistent with any adjustment recommended in such opinion.

 

4.10 No Adjustment. For the avoidance
of doubt, no adjustment shall be made to the terms of the Warrants solely as a result of (i) an adjustment to the conversion ratio
of the Class B Ordinary Shares into Ordinary Shares or the conversion of Class B Ordinary Shares into Ordinary Shares, in each
case, pursuant to the Amended and Restated Memorandum and Articles of Association, or (ii) the issuance of the Forward Purchase
Securities.

 

    10 

     

    

 

5. Transfer and Exchange of Warrants.

 

5.1. Registration of Transfer. The
Warrant Agent shall register the transfer, from time to time, of any outstanding Warrant upon the Warrant Register, upon surrender
of such Warrant for transfer, properly endorsed with signatures properly guaranteed and accompanied by appropriate instructions
for transfer. Upon any such transfer, a new Warrant representing an equal aggregate number of Warrants shall be issued and the
old Warrant shall be cancelled by the Warrant Agent. In the case of certificated Warrants, the Warrants so cancelled shall be delivered
by the Warrant Agent to the Company from time to time upon request.

 

5.2. Procedure for Surrender of Warrants.
Warrants may be surrendered to the Warrant Agent, together with a written request for exchange or transfer, and thereupon the Warrant
Agent shall issue in exchange therefor one or more new Warrants as requested by the Registered Holder of the Warrants so surrendered,
representing an equal aggregate number of Warrants; provided, however, that except as otherwise provided herein or
with respect to any Book-Entry Warrant, each Book-Entry Warrant may be transferred only in whole and only to the Depositary, to
another nominee of the Depositary, to a successor depository, or to a nominee of a successor depository; provided further,
however that in the event that a Warrant surrendered for transfer bears a restrictive legend (as in the case of the Private
Placement Warrants), the Warrant Agent shall not cancel such Warrant and issue new Warrants in exchange thereof until the Warrant
Agent has received an opinion of counsel for the Company stating that such transfer may be made and indicating whether the new
Warrants must also bear a restrictive legend.

 

5.3. Fractional Warrants. The Warrant
Agent shall not be required to effect any registration of transfer or exchange which shall result in the issuance of a warrant
certificate or book-entry position for a fraction of a warrant, except as part of the Units or the Forward Purchase Units.

 

5.4. Service Charges. No service
charge shall be made for any exchange or registration of transfer of Warrants.

 

5.5. Warrant Execution and Countersignature.
The Warrant Agent is hereby authorized to countersign and to deliver, in accordance with the terms of this Agreement, the Warrants
required to be issued pursuant to the provisions of this Section 5, and the Company, whenever required by the Warrant Agent,
shall supply the Warrant Agent with Warrants duly executed on behalf of the Company for such purpose.

 

5.6. Transfer of Warrants.

 

5.6.1. Outstanding Redeemable Warrants.
Prior to the Detachment Date, the Outstanding Redeemable Warrants may be transferred or exchanged only together with the Unit in
which such Outstanding redeemable Warrant is included, and only for the purpose of effecting, or in conjunction with, a transfer
or exchange of such Unit. Furthermore, each transfer of a Unit on the register relating to such Units shall operate also to transfer
the Outstanding Redeemable Warrants included in such Unit. Notwithstanding the foregoing, the provisions of this Section 5.6
shall have no effect on any transfer of Outstanding Redeemable Warrants on and after the Detachment Date.

 

5.6.2 Distributable Redeemable Warrants.
Prior to the Distribution Time, the right to receive the Distributable Redeemable Warrants may be transferred or exchanged only
together with the (i) Unit, if prior to the Detachment Date or (ii) if on or after the Detachment Date, the Ordinary Shares to
which such right to receive Distributable Redeemable Warrants is attached, and only for the purpose of effecting, or in conjunction
with, a transfer or exchange of such Unit or Ordinary Share, as applicable. Notwithstanding the foregoing, the provisions of this
Section 5.6 shall have no effect on any transfer of Distributable Redeemable Warrants on and after the Distribution Time.

 

5.6.3 Forward Purchase Warrants.
The Forward Purchase Warrants may be transferred only as provided in (i) Section 2.8 and (ii) as provided in the Forward
Purchase Agreement.

 

6. Redemption.

 

6.1. Redemption of Warrants When
the Reference Value Equals or Exceeds $18.00. Subject to Section 6.5 hereof, not less than all of the outstanding
Warrants may be redeemed, at the option of the Company, at any time during the Exercise Period, at the office of the Warrant
Agent, upon notice to the Registered Holders of the Warrants, as described in Section 6.3 below, at a Redemption Price
of $0.01 per Warrant, provided that (a) the Reference Value equals or exceeds $18.00 per share (subject to adjustment
in compliance with Section 4 hereof) and (b) there is an effective registration statement covering the issuance of the
Ordinary Shares issuable upon exercise of the Warrants, and a current prospectus relating thereto, available throughout the
30-day Redemption Period (as defined in Section 6.3 below).

 

    11 

     

    

 

6.2. Redemption of Warrants When the
Reference Value Equals or Exceeds $10.00. Subject to Section 6.5 hereof, not less than all of the outstanding Warrants
may be redeemed, at the option of the Company, at any time during the Exercise Period, at the office of the Warrant Agent, upon
notice to the Registered Holders of the Warrants, as described in Section 6.3 below, at a Redemption Price of $0.10 per
Warrant, provided that the Reference Value equals or exceeds $10.00 per share (subject to adjustment in compliance with
Section 4 hereof). During the 30-day Redemption Period in connection with a redemption pursuant to this Section 6.2,
Registered Holders of the Warrants may elect to exercise their Warrants on a “cashless basis” pursuant to subsection
3.3.1 and receive a number of Ordinary Shares determined by reference to the table below, based on the Redemption Date (calculated
for purposes of the table as the period to expiration of the Warrants) and the “Redemption Fair Market Value” (as such
term is defined in this Section 6.2) (a “Make-Whole Exercise”). Solely for purposes of this Section
6.2, the “Redemption Fair Market Value” shall mean the average of the daily volume-weighted average
trading prices of the Ordinary Shares during the ten (10) consecutive trading days ending on the third trading day prior to the
date on which the notice of redemption is sent to the Registered Holders pursuant to this Section 6.2, and the number of
months that the corresponding redemption date precedes the expiration date of the warrants, each as set forth in the table below.

 

	 	 	Redemption Fair Market Value of Ordinary Shares	 
	Redemption Date (period to

expiration of warrants)	 	≤10.00	 	 	11.00	 	 	12.00	 	 	 	13.00	 	14.00	 	 	15.00	 	 	16.00	 	 	17.00	 	 	>18.00	 
	60 months	 	 	0.2375	 	 	 	0.2586	 	 	 	0.2778	 	 	 	0.2952	 	 	 	0.3111	 	 	 	0.3254	 	 	 	0.3385	 	 	 	0.3503	 	 	 	0.3611	 
	57 months	 	 	0.2334	 	 	 	0.2552	 	 	 	0.2750	 	 	 	0.2930	 	 	 	0.3093	 	 	 	0.3242	 	 	 	0.3377	 	 	 	0.3500	 	 	 	0.3611	 
	54 months	 	 	0.2291	 	 	 	0.2515	 	 	 	0.2719	 	 	 	0.2905	 	 	 	0.3075	 	 	 	0.3229	 	 	 	0.3369	 	 	 	0.3496	 	 	 	0.3611	 
	51 months	 	 	0.2245	 	 	 	0.2475	 	 	 	0.2686	 	 	 	0.2879	 	 	 	0.3054	 	 	 	0.3214	 	 	 	0.3359	 	 	 	0.3491	 	 	 	0.3611	 
	48 months	 	 	0.2195	 	 	 	0.2433	 	 	 	0.2651	 	 	 	0.2850	 	 	 	0.3032	 	 	 	0.3198	 	 	 	0.3349	 	 	 	0.3486	 	 	 	0.3611	 
	45 months	 	 	0.2142	 	 	 	0.2386	 	 	 	0.2612	 	 	 	0.2819	 	 	 	0.3008	 	 	 	0.3181	 	 	 	0.3338	 	 	 	0.3481	 	 	 	0.3611	 
	42 months	 	 	0.2083	 	 	 	0.2336	 	 	 	0.2569	 	 	 	0.2785	 	 	 	0.2982	 	 	 	0.3162	 	 	 	0.3326	 	 	 	0.3475	 	 	 	0.3611	 
	39 months	 	 	0.2020	 	 	 	0.2280	 	 	 	0.2523	 	 	 	0.2747	 	 	 	0.2953	 	 	 	0.3141	 	 	 	0.3313	 	 	 	0.3469	 	 	 	0.3611	 
	36 months	 	 	0.1950	 	 	 	0.2220	 	 	 	0.2472	 	 	 	0.2705	 	 	 	0.2920	 	 	 	0.3118	 	 	 	0.3298	 	 	 	0.3462	 	 	 	0.3611	 
	33 months	 	 	0.1874	 	 	 	0.2153	 	 	 	0.2415	 	 	 	0.2659	 	 	 	0.2884	 	 	 	0.3092	 	 	 	0.3281	 	 	 	0.3454	 	 	 	0.3611	 
	30 months	 	 	0.1791	 	 	 	0.2078	 	 	 	0.2351	 	 	 	0.2606	 	 	 	0.2844	 	 	 	0.3062	 	 	 	0.3263	 	 	 	0.3445	 	 	 	0.3611	 
	27 months	 	 	0.1698	 	 	 	0.1995	 	 	 	0.2279	 	 	 	0.2547	 	 	 	0.2798	 	 	 	0.3029	 	 	 	0.3241	 	 	 	0.3435	 	 	 	0.3611	 
	24 months	 	 	0.1594	 	 	 	0.1901	 	 	 	0.2198	 	 	 	0.2480	 	 	 	0.2745	 	 	 	0.2990	 	 	 	0.3217	 	 	 	0.3423	 	 	 	0.3611	 
	21 months	 	 	0.1478	 	 	 	0.1795	 	 	 	0.2105	 	 	 	0.2402	 	 	 	0.2684	 	 	 	0.2946	 	 	 	0.3188	 	 	 	0.3409	 	 	 	0.3611	 
	18 months	 	 	0.1347	 	 	 	0.1673	 	 	 	0.1997	 	 	 	0.2312	 	 	 	0.2612	 	 	 	0.2893	 	 	 	0.3154	 	 	 	0.3393	 	 	 	0.3611	 
	15 months	 	 	0.1198	 	 	 	0.1531	 	 	 	0.1870	 	 	 	0.2204	 	 	 	0.2526	 	 	 	0.2830	 	 	 	0.3113	 	 	 	0.3374	 	 	 	0.3611	 
	12 months	 	 	0.1026	 	 	 	0.1365	 	 	 	0.1719	 	 	 	0.2074	 	 	 	0.2421	 	 	 	0.2752	 	 	 	0.3063	 	 	 	0.3349	 	 	 	0.3611	 
	9 months	 	 	0.0828	 	 	 	0.1167	 	 	 	0.1535	 	 	 	0.1914	 	 	 	0.2292	 	 	 	0.2656	 	 	 	0.3000	 	 	 	0.3319	 	 	 	0.3611	 
	6 months	 	 	0.0592	 	 	 	0.0923	 	 	 	0.1305	 	 	 	0.1713	 	 	 	0.2129	 	 	 	0.2536	 	 	 	0.2922	 	 	 	0.3282	 	 	 	0.3611	 
	3 months	 	 	0.0302	 	 	 	0.0601	 	 	 	0.0997	 	 	 	0.1453	 	 	 	0.1929	 	 	 	0.2397	 	 	 	0.2837	 	 	 	0.3242	 	 	 	0.3611	 
	0 months	 	 	0.0000	 	 	 	0.0000	 	 	 	0.0417	 	 	 	0.1154	 	 	 	0.1786	 	 	 	0.2333	 	 	 	0.2813	 	 	 	0.3235	 	 	 	0.3611	 

 

The exact Redemption Fair Market Value
and Redemption Date may not be set forth in the table above, in which case, if the Redemption Fair Market Value is between two
values in the table or the Redemption Date is between two redemption dates in the table, the number of Ordinary Shares to be issued
for each Warrant exercised in a Make-Whole Exercise shall be determined by a straight-line interpolation between the number of
shares set forth for the higher and lower Redemption Fair Market Values and the earlier and later redemption dates, as applicable,
based on a 365- or 366-day year, as applicable.

 

The share prices set forth in the
column headings of the table above shall be adjusted as of any date on which the number of shares issuable upon exercise of a
Warrant or the Exercise Price is adjusted pursuant to Section 4 hereof. If the number of shares issuable upon exercise
of a Warrant is adjusted pursuant to Section 4 hereof, the adjusted share prices in the column headings shall equal the share
prices immediately prior to such adjustment, multiplied by a fraction, the numerator of which is the number of shares
deliverable upon exercise of a Warrant immediately prior to such adjustment and the denominator of which is the number of
shares deliverable upon exercise of a Warrant as so adjusted. The number of shares in the table above shall be adjusted in
the same manner and at the same time as the number of shares issuable upon exercise of a Warrant. If the Exercise Price of a
warrant is adjusted, (a) in the case of an adjustment pursuant to Section 4.4 hereof, the adjusted share prices in the column
headings shall equal the share prices immediately prior to such adjustment multiplied by a fraction, the numerator of which
is the higher of the Market Value and the Newly Issued Price and the denominator of which is $10.00 and (b) in the case of an
adjustment pursuant to Section 4.1.2 hereof, the adjusted share prices in the column headings shall equal the share
prices immediately prior to such adjustment less the decrease in the Exercise Price pursuant to such Exercise Price
adjustment. In no event shall the number of shares issued in connection with a Make-Whole Exercise exceed 0.3611 Ordinary
Shares per Warrant (subject to adjustment)

 

    12 

     

    

 

6.3. Date Fixed for, and Notice of,
Redemption; Redemption Price; Reference Value. In the event that the Company elects to redeem the Warrants pursuant to Sections
6.1 or 6.2, the Company shall fix a date for the redemption (the “Redemption Date”). Notice
of redemption shall be mailed by first class mail, postage prepaid, by the Company not less than thirty (30) days prior to the
Redemption Date (the “30-day Redemption Period”) to the Registered Holders of the Warrants to be redeemed
at their last addresses as they shall appear on the registration books. Any notice mailed in the manner herein provided shall be
conclusively presumed to have been duly given whether or not the Registered Holder received such notice. As used in this Agreement,
(a) “Redemption Price” shall mean the price per Warrant at which any Warrants are redeemed pursuant to
Sections 6.1 or 6.2 and (b) “Reference Value” shall mean the daily volume-weighted average
price of the Ordinary Shares (as adjusted for share splits, share dividends, reorganizations, recapitalizations and the like) for
any twenty (20) trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company
sends the notice of redemption to the Registered Holder.

 

6.4. Exercise after Notice of Redemption.
The Warrants may be exercised, for cash (or on a “cashless basis” in accordance with Section 6.2 of this Agreement)
at any time after notice of redemption shall have been given by the Company pursuant to Section 6.3 hereof and prior to
the Redemption Date. On and after the Redemption Date, the record holder of the Warrants shall have no further rights except to
receive, upon surrender of the Warrants, the Redemption Price.

 

6.5. Exclusion of Private Placement
Warrants. The Company agrees that the redemption rights provided in Section 6.1 hereof shall not apply to the Private
Placement Warrants if at the time of the redemption such Private Placement Warrants continue to be held by the Sponsor, Maxim or
their Permitted Transferees. However, once such Private Placement Warrants are transferred (other than to Permitted Transferees
in accordance with Section 2.6 hereof), the Company may redeem the Private Placement Warrants pursuant to Section 6.1
hereof, provided that the criteria for redemption are met, including the opportunity of the holder of such Private Placement Warrants
to exercise the Private Placement Warrants prior to redemption pursuant to Section 6.4 hereof. Private Placement Warrants
that are transferred to persons other than Permitted Transferees shall upon such transfer cease to be Private Placement Warrants
and shall become Redeemable Warrants under this Agreement, including for purposes of Section 9.8 hereof.

 

7. Other Provisions Relating to Rights
of Holders of Warrants.

 

7.1. No Rights as Shareholder. A
Warrant does not entitle the Registered Holder thereof to any of the rights of a shareholder of the Company, including, without
limitation, the right to receive dividends, or other distributions, exercise any preemptive rights to vote or to consent or to
receive notice as shareholders in respect of the meetings of shareholders or the election of directors of the Company or any other
matter.

 

7.2. Lost, Stolen, Mutilated, or Destroyed
Warrants. If any Warrant is lost, stolen, mutilated, or destroyed, the Company and the Warrant Agent may on such terms as to
indemnity or otherwise as they may in their discretion impose (which shall, in the case of a mutilated Warrant, include the surrender
thereof), issue a new Warrant of like denomination, tenor, and date as the Warrant so lost, stolen, mutilated, or destroyed. Any
such new Warrant shall constitute a substitute contractual obligation of the Company, whether or not the allegedly lost, stolen,
mutilated, or destroyed Warrant shall be at any time enforceable by anyone.

 

    13 

     

    

 

7.3. Reservation of Ordinary Shares.
The Company shall at all times reserve and keep available a number of its authorized but unissued Ordinary Shares that shall be
sufficient to permit the exercise in full of all outstanding Warrants issued pursuant to this Agreement.

 

7.4. Registration of Ordinary Shares; Cashless Exercise at
Company’s Option.

 

7.4.1. Registration of the Ordinary
Shares. The Company agrees that as soon as practicable, but in no event later than fifteen (15) Business Days after the closing
of its initial Business Combination, it shall use its commercially reasonable efforts to file with the Commission a registration
statement for the registration, under the Securities Act, of the Ordinary Shares issuable upon exercise of the Warrants. The Company
shall use its commercially reasonable efforts to cause the same to become effective within sixty (60) Business Days following the
closing of its initial Business Combination and to maintain the effectiveness of such registration statement, and a current prospectus
relating thereto, until the expiration or redemption of the Warrants in accordance with the provisions of this Agreement. If any
such registration statement has not been declared effective by the sixtieth (60th) Business Day following the closing of the Business
Combination, holders of the Warrants shall have the right, during the period beginning on the sixty-first (61st) Business Day after
the closing of the Business Combination and ending upon such registration statement being declared effective by the Commission,
and during any other period when the Company shall fail to have maintained an effective registration statement covering the issuance
of the Ordinary Shares issuable upon exercise of the Warrants, to exercise such Warrants on a “cashless basis,” by
exchanging the Warrants (in accordance with Section 3(a)(9) of the Securities Act or another exemption) for that number of Ordinary
Shares equal to the lesser of (A) the quotient obtained by dividing (x) the product of the number of Ordinary Shares underlying
the Warrants, multiplied by the excess of the “Fair Market Value” (as defined below) less the Warrant Price by (y)
the Fair Market Value and (B) 0.3611 per Warrant. Solely for purposes of this subsection 7.4.1, “Fair Market
Value” shall mean the daily volume-weighted average price of the Ordinary Shares as reported during the ten (10)
trading day period ending on the trading day prior to the date that notice of exercise is received by the Warrant Agent from the
holder of such Warrants or its securities broker or intermediary. The date that notice of “cashless exercise” is received
by the Warrant Agent shall be conclusively determined by the Warrant Agent. In connection with the “cashless exercise”
of a Redeemable Warrant, the Company shall, upon request, provide the Warrant Agent with an opinion of counsel for the Company
(which shall be an outside law firm with securities law experience) stating that (i) the exercise of the Warrants on a “cashless
basis” in accordance with this subsection 7.4.1 is not required to be registered under the Securities Act and (ii)
the Ordinary Shares issued upon such exercise shall be freely tradable under United States federal securities laws by anyone who
is not an affiliate (as such term is defined in Rule 144 under the Securities Act) of the Company and, accordingly, shall not be
required to bear a restrictive legend. Except as provided in subsection 7.4.3, for the avoidance of doubt, unless and until
all of the Warrants have been exercised or have expired, the Company shall continue to be obligated to comply with its registration
obligations under the first three sentences of this subsection 7.4.1.

 

7.4.2 Registration of the Ordinary Shares
Underlying the Forward Purchase Warrants. If the Company has not caused a registration statement for the registration of the
Ordinary Shares issuable upon exercise of the Forward Purchase Warrants to be declared effective as of the time required by, and
pursuant to the conditions set forth in, the Registration Rights Agreement, holders of the Forward Purchase Warrants shall have
the right, during the period beginning on the first Business Day following such time and ending upon such registration statement
being declared effective by the Commission, and during any other period when the Company shall fail to have maintained an effective
registration statement covering the issuance of the Ordinary Shares issuable upon exercise of the Forward Purchase Warrants, to
exercise such Warrants on a “cashless basis,” as provided in subsection 7.4.1 above.

 

7.4.3. Cashless Exercise at Company’s
Option. If the Ordinary Shares are at the time of any exercise of a Warrant not listed on a national securities exchange such
that they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company
may, at its option, (i) require holders of Warrants who exercise Warrants to exercise such Warrants on a “cashless basis”
in accordance with Section 3(a)(9) of the Securities Act as described in subsection 7.4.1 and (ii) in the event the Company
so elects, the Company shall (x) not be required to file or maintain in effect a registration statement for the registration, under
the Securities Act, of the Ordinary Shares issuable upon exercise of the Warrants, notwithstanding anything in this Agreement to
the contrary, and (y) use its commercially reasonable efforts to register or qualify for sale the Ordinary Shares issuable upon
exercise of the Warrants under applicable blue sky laws to the extent an exemption is not available.

 

    14 

     

    

 

8. Concerning the Warrant Agent and
Other Matters.

 

8.1. Payment of Taxes. The Company
shall from time to time promptly pay all taxes and charges that may be imposed upon the Company or the Warrant Agent in respect
of the issuance or delivery of Ordinary Shares upon the exercise of the Warrants, but the Company shall not be obligated to pay
any transfer taxes in respect of the Warrants or such shares.

 

8.2. Resignation, Consolidation, or Merger of Warrant Agent.

 

8.2.1. Appointment of Successor Warrant
Agent. The Warrant Agent, or any successor to it hereafter appointed, may resign its duties and be discharged from all further
duties and liabilities hereunder after giving sixty (60) days’ notice in writing to the Company. If the office of the Warrant
Agent becomes vacant by resignation or incapacity to act or otherwise, the Company shall appoint in writing a successor Warrant
Agent in place of the Warrant Agent. If the Company shall fail to make such appointment within a period of thirty (30) days after
it has been notified in writing of such resignation or incapacity by the Warrant Agent or by the holder of a Warrant (who shall,
with such notice, submit his, her or its Warrant for inspection by the Company), then the holder of any Warrant may apply to the
Supreme Court of the State of New York for the County of New York for the appointment of a successor Warrant Agent at the Company’s
cost. Any successor Warrant Agent, whether appointed by the Company or by such court, shall be a corporation or other entity organized
and existing under the laws of the State of New York, in good standing and having its principal office in the United States of
America, and authorized under such laws to exercise corporate trust powers and subject to supervision or examination by federal
or state authority. After appointment, any successor Warrant Agent shall be vested with all the authority, powers, rights, immunities,
duties, and obligations of its predecessor Warrant Agent with like effect as if originally named as Warrant Agent hereunder, without
any further act or deed; but if for any reason it becomes necessary or appropriate, the predecessor Warrant Agent shall execute
and deliver, at the expense of the Company, an instrument transferring to such successor Warrant Agent all the authority, powers,
and rights of such predecessor Warrant Agent hereunder; and upon request of any successor Warrant Agent the Company shall make,
execute, acknowledge, and deliver any and all instruments in writing for more fully and effectually vesting in and confirming to
such successor Warrant Agent all such authority, powers, rights, immunities, duties, and obligations.

 

8.2.2. Notice of Successor Warrant Agent.
In the event a successor Warrant Agent shall be appointed, the Company shall give notice thereof to the predecessor Warrant Agent
and the Transfer Agent for the Ordinary Shares not later than the effective date of any such appointment.

 

8.2.3. Merger or Consolidation of Warrant
Agent. Any entity into which the Warrant Agent may be merged or with which it may be consolidated or any entity resulting from
any merger or consolidation to which the Warrant Agent shall be a party shall be the successor Warrant Agent under this Agreement
without any further act.

 

8.3. Fees and Expenses of Warrant Agent.

 

8.3.1. Remuneration. The Company
agrees to pay the Warrant Agent reasonable remuneration for its services as such Warrant Agent hereunder and shall, pursuant to
its obligations under this Agreement, reimburse the Warrant Agent upon demand for all expenditures that the Warrant Agent may reasonably
incur in the execution of its duties hereunder.

 

8.3.2. Further Assurances. The Company
agrees to perform, execute, acknowledge, and deliver or cause to be performed, executed, acknowledged, and delivered all such further
and other acts, instruments, and assurances as may reasonably be required by the Warrant Agent for the carrying out or performing
of the provisions of this Agreement.

 

8.4. Liability of Warrant Agent.

 

8.4.1. Reliance on Company
Statement. Whenever in the performance of its duties under this Agreement, the Warrant Agent shall deem it necessary or
desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder,
such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed to be
conclusively proved and established by a statement signed by the Chief Executive Officer, the President, the Chief Financial
Officer, Chief Operating Officer, the General Counsel, the Secretary or the Chairman of the Board of the Company and
delivered to the Warrant Agent. The Warrant Agent may rely upon such statement for any action taken or suffered in good faith
by it pursuant to the provisions of this Agreement.

 

    15 

     

    

 

8.4.2. Indemnity. The Warrant Agent
shall be liable hereunder only for its own gross negligence, willful misconduct, fraud or bad faith. The Company agrees to indemnify
the Warrant Agent and save it harmless against any and all liabilities, including judgments, out-of-pocket costs and reasonable
outside counsel fees, for anything done or omitted by the Warrant Agent in the execution of this Agreement, except as a result
of the Warrant Agent’s gross negligence, willful misconduct, fraud or bad faith.

  

8.4.3. Exclusions. The Warrant Agent
shall have no responsibility with respect to the validity of this Agreement or with respect to the validity or execution of any
Warrant (except its countersignature thereof). The Warrant Agent shall not be responsible for any breach by the Company of any
covenant or condition contained in this Agreement or in any Warrant. The Warrant Agent shall not be responsible to make any adjustments
required under the provisions of Section 4 hereof or responsible for the manner, method, or amount of any such adjustment
or the ascertaining of the existence of facts that would require any such adjustment; nor shall it by any act hereunder be deemed
to make any representation or warranty as to the authorization or reservation of any Ordinary Shares to be issued pursuant to this
Agreement, the Amended and Restated Memorandum and Articles of Association of the Company or any Warrant or as to whether any Ordinary
Shares shall, when issued, be valid and fully paid and nonassessable.

 

8.5. Acceptance of Agency. The Warrant
Agent hereby accepts the agency established by this Agreement and agrees to perform the same upon the terms and conditions herein
set forth and among other things, shall account promptly to the Company with respect to Warrants exercised and concurrently account
for, and pay to the Company, all monies received by the Warrant Agent for the purchase of Ordinary Shares through the exercise
of the Warrants.

 

8.6. Waiver. The Warrant Agent has
no right of set-off or any other right, title, interest or claim of any kind (“Claim”) in, or to any
distribution of, the Trust Account (as defined in that certain Investment Management Trust Agreement, dated as of the date hereof,
by and between the Company and Continental Stock Transfer & Trust Company as trustee thereunder) and hereby agrees not to seek
recourse, reimbursement, payment or satisfaction for any Claim against the Trust Account for any reason whatsoever. The Warrant
Agent hereby waives any and all Claims against the Trust Account and any and all rights to seek access to the Trust Account.

 

9. Miscellaneous Provisions.

 

9.1. Successors. All the covenants
and provisions of this Agreement by or for the benefit of the Company or the Warrant Agent shall bind and inure to the benefit
of their respective successors and assigns.

 

9.2. Notices. Any notice, statement
or demand authorized by this Agreement to be given or made by the Warrant Agent or by the holder of any Warrant to or on the Company
shall be sufficiently given when so delivered if by hand or overnight delivery or if sent by certified mail or private courier
service within five (5) days after deposit of such notice, postage prepaid, addressed (until another address is filed in writing
by the Company with the Warrant Agent), as follows:

 

Medicus Sciences Acquisition Corp.

152 West 57th Street, Floor 20

New York, NY 10019

 

with a copy to:

 

Ellenoff Grossman & Schole LLP

1345 Avenue of the Americas

New York, NY 10105

Attn: Barry I. Grossman, Esq.

 

Any notice, statement or demand
authorized by this Agreement to be given or made by the holder of any Warrant or by the Company to or on the Warrant Agent
shall be sufficiently given (i) if by email, when the email is sent, (ii) if by hand or overnight delivery, when so delivered
or (iii) if sent by certified mail or private courier service, within five (5) days after deposit of such notice, postage
prepaid, addressed (until another address is filed in writing by the Warrant Agent with the Company), as follows:

 

    16 

     

    

 

Continental Stock Transfer & Trust Company

One State Street, 30th Floor 

New York, NY 10004

Attention: Compliance Department

 

9.3. Applicable Law and Exclusive Forum.
The validity, interpretation, and performance of this Agreement and of the Warrants shall be governed in all respects by the laws
of the State of New York. Subject to applicable law, the Company hereby agrees that any action, proceeding or claim against it
arising out of or relating in any way to this Agreement shall be brought and enforced in the courts of the State of New York or
the United States District Court for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction
shall be exclusive forum for any such action, proceeding or claim. The Company hereby waives any objection to such exclusive jurisdiction
and that such courts represent an inconvenient forum. Notwithstanding the foregoing, the provisions of this paragraph will not
apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal district
courts of the United States of America are the sole and exclusive forum.

 

Any person or entity purchasing or otherwise
acquiring any interest in the Warrants shall be deemed to have notice of and to have consented to the forum provisions in this
Section 9.3. If any action, the subject matter of which is within the scope the forum provisions above, is filed in a court
other than a court located within the State of New York or the United States District Court for the Southern District of New York
(a “foreign action”) in the name of any warrant holder, such warrant holder shall be deemed to have consented to: (x)
the personal jurisdiction of the state and federal courts located within the State of New York or the United States District Court
for the Southern District of New York in connection with any action brought in any such court to enforce the forum provisions (an
 “enforcement action”), and (y) having service of process made upon such warrant holder in any such enforcement action
by service upon such warrant holder’s counsel in the foreign action as agent for such warrant holder.

 

9.4. Persons Having Rights under this
Agreement. Nothing in this Agreement shall be construed to confer upon, or give to, any person, corporation or other entity
other than the parties hereto and the Registered Holders of the Warrants and, for purposes of Sections 7.4, 9.4 and 9.8, Maxim
and/or its designees, any right, remedy, or claim under or by reason of this Agreement or of any covenant, condition, stipulation,
promise, or agreement hereof. All covenants, conditions, stipulations, promises, and agreements contained in this Agreement shall
be for the sole and exclusive benefit of the parties hereto and, for purposes of Sections 7.4, 9.4 and 9.8, Maxim and/or its designees,
and their successors and assigns and of the Registered Holders of the Warrants.

 

9.5. Examination of the Warrant Agreement.
A copy of this Agreement shall be available at all reasonable times at the office of the Warrant Agent in the United States of
America, for inspection by the Registered Holder of any Warrant. The Warrant Agent may require any such holder to submit such holder’s
Warrant for inspection by the Warrant Agent.

 

9.6. Counterparts. This Agreement
may be executed in any number of original or facsimile counterparts and each of such counterparts shall for all purposes be deemed
to be an original, and all such counterparts shall together constitute but one and the same instrument.

 

9.7. Effect of Headings. The section
headings herein are for convenience only and are not part of this Agreement and shall not affect the interpretation thereof.

 

9.8. Amendments. This
Agreement may be amended by the parties hereto without the consent of any Registered Holder for the purpose of curing any
ambiguity or to correct any mistake, including to conform the provisions hereof to the description of the terms of the
Warrants and this Agreement set forth in the Prospectus, or defective provision contained herein. All other modifications or
amendments, including any modification or amendment to increase the Warrant Price or shorten the Exercise Period, shall
require the vote or written consent of the Registered Holders of 50% of the then-outstanding Redeemable Warrants and, solely
with respect to any amendment to the terms of the Private Placement Warrants or any provision of this Agreement with respect
to the Private Placement Warrants, 50% of the then-outstanding Private Placement Warrants and, solely with respect to any
amendment to the terms of the Forward Purchase Warrants or any provision of this Agreement with respect to the Forward
Purchase Warrants, 50% of the then-outstanding Forward Purchase Warrants. Notwithstanding the foregoing, the Company may
lower the Warrant Price or extend the duration of the Exercise Period pursuant to Sections 3.1 and 3.2,
respectively, without the consent of the Registered Holders. The Forward Purchase Warrants have no right to vote on
amendments to this Agreement, except with respect to Sections 2.8, 5.6.3 and 7.4.2.

 

    17 

     

    

 

9.9. Severability. This Agreement
shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect the validity
or enforceability of this Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable
term or provision, the parties hereto intend that there shall be added as a part of this Agreement a provision as similar in terms
to such invalid or unenforceable provision as may be possible and be valid and enforceable.

 

Exhibit A — Form of Warrant Certificate

 

Exhibit B Legend — Sponsor Private Placement Warrants

 

Exhibit C Legend — Maxim Private Placement Warrants

 

Exhibit D Legend — Forward Purchase Warrants

 

    18 

     

    

 

IN WITNESS WHEREOF, the parties hereto
have caused this Agreement to be duly executed as of the date first above written.

 

	 	MEDICUS SCIENCES ACQUISITION CORP.
	 	 	 
	 	By:	/s/
Michael Castor
	 	 	Name: Michael Castor
	 	 	Title: Chief Executive Officer
	 	 
	 	CONTINENTAL STOCK TRANSFER & TRUST COMPANY, as Warrant Agent
	 	 	 
	 	By:	/s/
Erika Young
	 	 	Name: Erika Young
	 	 	Title: Vice President

 

     

     

    

 

EXHIBIT A

 

[FACE]

 

Number

 

Warrants

 

THIS WARRANT SHALL BE VOID IF NOT EXERCISED
PRIOR TO

THE EXPIRATION OF THE EXERCISE PERIOD PROVIDED FOR

IN THE WARRANT AGREEMENT DESCRIBED BELOW

 

MEDICUS SCIENCES ACQUISITION CORP.

Incorporated Under the Laws of the Cayman
Islands

 

CUSIP G5960S 124

 

Warrant Certificate 

 

This Warrant Certificate certifies that
______________, or registered assigns, is the registered holder of ________________ warrant(s) (the “Warrants”
and each, a “Warrant”) to purchase Class A ordinary shares, $0.0001 par value (the “Ordinary
Shares”), of Medicus Sciences Acquisition Corp., a Cayman Islands exempted company (the “Company”).
Each Warrant entitles the holder, upon exercise during the period set forth in the Warrant Agreement referred to below, to receive
from the Company that number of fully paid and nonassessable Ordinary Shares as set forth below, at the exercise price (the “Exercise
Price”) as determined pursuant to the Warrant Agreement, payable in lawful money (or through “cashless
exercise” as provided for in the Warrant Agreement) of the United States of America upon surrender of this Warrant
Certificate and payment of the Exercise Price at the office or agency of the Warrant Agent referred to below, subject to the conditions
set forth herein and in the Warrant Agreement. Defined terms used in this Warrant Certificate but not defined herein shall have
the meanings given to them in the Warrant Agreement.

 

Each whole Warrant is initially exercisable
for one fully paid and non-assessable Ordinary Share. Fractional shares shall not be issued upon exercise of any Warrant. If, upon
the exercise of Warrants, a holder would be entitled to receive a fractional interest in an Ordinary Share, the Company shall,
upon exercise, round down to the nearest whole number the number of Ordinary Shares to be issued to the Warrant holder. The number
of Ordinary Shares issuable upon exercise of the Warrants is subject to adjustment upon the occurrence of certain events as set
forth in the Warrant Agreement.

 

The initial Exercise Price per Ordinary
Share for any Warrant is equal to $11.50 per share. The Exercise Price is subject to adjustment upon the occurrence of certain
events as set forth in the Warrant Agreement.

 

Subject to the conditions set forth in
the Warrant Agreement, the Warrants may be exercised only during the Exercise Period and to the extent not exercised by the end
of such Exercise Period, such Warrants shall become void. The Warrants may be redeemed, subject to certain conditions, as set forth
in the Warrant Agreement.

 

Reference is hereby made to the further
provisions of this Warrant Certificate set forth on the reverse hereof and such further provisions shall for all purposes have
the same effect as though fully set forth at this place.

 

This Warrant Certificate shall not be valid
unless countersigned by the Warrant Agent, as such term is used in the Warrant Agreement. This Warrant Certificate shall be governed
by and construed in accordance with the internal laws of the State of New York.

 

     

     

    

 

	 	MEDICUS SCIENCES ACQUISITION CORP.
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title: Authorized Signatory

   

	 	CONTINENTAL STOCK TRANSFER & TRUST COMPANY, AS WARRANT AGENT
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

[REVERSE]

 

The Warrants evidenced by this Warrant
Certificate are part of a duly authorized issue of Warrants entitling the holder on exercise to receive Ordinary Shares and are
issued or to be issued pursuant to a Warrant Agreement dated as of [_____], 2021 (the “Warrant Agreement”),
duly executed and delivered by the Company to Continental Stock Transfer & Trust Company, a New York limited purpose trust
company, as warrant agent (the “Warrant Agent”), which Warrant Agreement is hereby incorporated by reference
in and made a part of this instrument and is hereby referred to for a description of the rights, limitation of rights, obligations,
duties and immunities thereunder of the Warrant Agent, the Company and the holders (the words “holders”
or “holder” meaning the Registered Holders or Registered Holder, respectively) of the Warrants. A copy
of the Warrant Agreement may be obtained by the holder hereof upon written request to the Company. Defined terms used in this Warrant
Certificate but not defined herein shall have the meanings given to them in the Warrant Agreement.

 

Warrants may be exercised at any time during
the Exercise Period set forth in the Warrant Agreement. The holder of Warrants evidenced by this Warrant Certificate may exercise
them by surrendering this Warrant Certificate, with the form of Election to Purchase set forth hereon properly completed and executed,
together with payment of the Exercise Price as specified in the Warrant Agreement (or through “cashless exercise”
as provided for in the Warrant Agreement) at the principal corporate trust office of the Warrant Agent. In the event that upon
any exercise of Warrants evidenced hereby the number of Warrants exercised shall be less than the total number of Warrants evidenced
hereby, there shall be issued to the holder hereof or his, her or its assignee, a new Warrant Certificate evidencing the number
of Warrants not exercised.

 

Notwithstanding anything else in this Warrant
Certificate or the Warrant Agreement, no Warrant may be exercised unless at the time of exercise (i) a registration statement covering
the issuance of the Ordinary Shares to be issued upon exercise is effective under the Securities Act and (ii) a prospectus thereunder
relating to the Ordinary Shares is current, except through “cashless exercise” as provided for in the Warrant
Agreement.

 

The Warrant Agreement provides that upon
the occurrence of certain events the number of Ordinary Shares issuable upon exercise of the Warrants set forth on the face hereof
may, subject to certain conditions, be adjusted. If, upon exercise of a Warrant, the holder thereof would be entitled to receive
a fractional interest in an Ordinary Share, the Company shall, upon exercise, round down to the nearest whole number of Ordinary
Shares to be issued to the holder of the Warrant.

 

Warrant Certificates, when surrendered
at the principal corporate trust office of the Warrant Agent by the Registered Holder thereof in person or by legal representative
or attorney duly authorized in writing, may be exchanged, in the manner and subject to the limitations provided in the Warrant
Agreement, but without payment of any service charge, for another Warrant Certificate or Warrant Certificates of like tenor evidencing
in the aggregate a like number of Warrants.

 

     

     

    

 

Upon due presentation for registration
of transfer of this Warrant Certificate at the office of the Warrant Agent a new Warrant Certificate or Warrant Certificates of
like tenor and evidencing in the aggregate a like number of Warrants shall be issued to the transferee(s) in exchange for this
Warrant Certificate, subject to the limitations provided in the Warrant Agreement, without charge except for any tax or other governmental
charge imposed in connection therewith.

 

The Company and the Warrant Agent may deem
and treat the Registered Holder(s) hereof as the absolute owner(s) of this Warrant Certificate (notwithstanding any notation of
ownership or other writing hereon made by anyone), for the purpose of any exercise hereof, of any distribution to the holder(s)
hereof, and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary.
Neither the Warrants nor this Warrant Certificate entitles any holder hereof to any rights of a shareholder of the Company. 

 

Election to Purchase

 

(To Be Executed Upon Exercise of Warrant)

 

The undersigned hereby irrevocably elects
to exercise the right, represented by this Warrant Certificate, to receive Ordinary Shares and herewith tenders payment for such
Ordinary Shares to the order of Medicus Sciences Acquisition Corp. (the “Company”) in the amount of $_______
in accordance with the terms hereof. The undersigned requests that a certificate for such Ordinary Shares be registered in the
name of _______________, whose address is __________________________________ and that such Ordinary Shares be delivered to _______________
whose address is __________________________________. If said number of Ordinary Shares is less than all of the Ordinary Shares
purchasable hereunder, the undersigned requests that a new Warrant Certificate representing the remaining balance of such Ordinary
Shares be registered in the name of _______________, whose address is __________________________________ and that such Warrant
Certificate be delivered to _______________, whose address is __________________________________.

 

In the event that the Warrant has been
called for redemption by the Company pursuant to Section 6.2 of the Warrant Agreement and a holder thereof elects to exercise
its Warrant pursuant to a Make-Whole Exercise, the number of Ordinary Shares that this Warrant is exercisable for shall be determined
in accordance with subsection 3.3.1(b) or Section 6.2 of the Warrant Agreement, as applicable.

 

In the event that the Warrant is a Private
Placement Warrant that is to be exercised on a “cashless” basis pursuant to subsection 3.3.1(b) of the Warrant
Agreement, the number of Ordinary Shares that this Warrant is exercisable for shall be determined in accordance with subsection
3.3.1(b) of the Warrant Agreement.

 

In the event that the Warrant is to be
exercised on a “cashless” basis pursuant to Section 7.4 of the Warrant Agreement, the number of Ordinary Shares
that this Warrant is exercisable for shall be determined in accordance with Section 7.4 of the Warrant Agreement.

 

In the event that the Warrant may be exercised,
to the extent allowed by the Warrant Agreement, through cashless exercise (i) the number of Ordinary Shares that this Warrant is
exercisable for would be determined in accordance with the relevant section of the Warrant Agreement which allows for such cashless
exercise and (ii) the holder hereof shall complete the following: The undersigned hereby irrevocably elects to exercise the right,
represented by this Warrant Certificate, through the cashless exercise provisions of the Warrant Agreement, to receive Ordinary
Shares. If said number of shares is less than all of the Ordinary Shares purchasable hereunder (after giving effect to the cashless
exercise), the undersigned requests that a new Warrant Certificate representing the remaining balance of such Ordinary Shares be
registered in the name of _______________, whose address is __________________________________ and that such Warrant Certificate
be delivered to _______________, whose address is __________________________________.

 

[Signature Page Follows]

 

     

     

    

 

Date:         , 20__

 

	 	 	(Signature)
	 	 
	 	 	(Address)
	 	 	 
	 	 	(Tax Identification Number)
	 	 	 
	Signature Guaranteed:	 	 
	 	 	 

 

THE SIGNATURE(S) SHOULD BE GUARANTEED
BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN
AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15 UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED).

 

EXHIBIT B

 

LEGEND FOR SPONSOR PRIVATE PLACEMENT WARRANTS

 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED, SOLD,
TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND ANY APPLICABLE STATE SECURITIES
LAWS OR AN EXEMPTION FROM REGISTRATION IS AVAILABLE. IN ADDITION, SUBJECT TO ANY ADDITIONAL LIMITATIONS ON TRANSFER DESCRIBED IN
THE LETTER AGREEMENT BY AND AMONG MEDICUS SCIENCES ACQUISITION CORP. (THE “COMPANY”), MEDICUS SCIENCES
HOLDINGS LLC AND THE OTHER PARTIES THERETO, THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD OR TRANSFERRED PRIOR
TO THE DATE THAT IS THIRTY (30) DAYS AFTER THE DATE UPON WHICH THE COMPANY COMPLETES ITS INITIAL BUSINESS COMBINATION (AS DEFINED
IN SECTION 3 OF THE WARRANT AGREEMENT REFERRED TO HEREIN) EXCEPT TO A PERMITTED TRANSFEREE (AS DEFINED IN SECTION 2 OF THE WARRANT
AGREEMENT) WHO AGREES IN WRITING WITH THE COMPANY TO BE SUBJECT TO SUCH TRANSFER PROVISIONS.

 

SECURITIES EVIDENCED BY THIS CERTIFICATE
AND CLASS A ORDINARY SHARES OF THE COMPANY ISSUED UPON EXERCISE OF SUCH SECURITIES SHALL BE ENTITLED TO REGISTRATION RIGHTS UNDER
A REGISTRATION RIGHTS AGREEMENT TO BE EXECUTED BY THE COMPANY.

 

EXHIBIT C

 

LEGEND FOR MAXIM PRIVATE PLACEMENT WARRANTS

 

THE SECURITIES REPRESENTED BY THIS
CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND
MAY NOT BE OFFERED, SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, AND ANY APPLICABLE STATE SECURITIES LAWS OR AN EXEMPTION FROM REGISTRATION IS AVAILABLE. IN ADDITION, SUBJECT TO ANY
ADDITIONAL LIMITATIONS ON TRANSFER DESCRIBED IN THE PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT BY AND BETWEEN MEDICUS
SCIENCES ACQUISITION CORP. (THE “COMPANY”) AND MAXIM PARTNERS LLC, THE SECURITIES REPRESENTED BY
THIS CERTIFICATE MAY NOT BE SOLD OR TRANSFERRED PRIOR TO THE DATE THAT IS THIRTY (30) DAYS AFTER THE DATE UPON
WHICH THE COMPANY COMPLETES ITS INITIAL BUSINESS COMBINATION (AS DEFINED IN SECTION 3 OF THE WARRANT AGREEMENT REFERRED
TO HEREIN) EXCEPT TO A PERMITTED TRANSFEREE (AS DEFINED IN SECTION 2 OF THE WARRANT AGREEMENT) WHO AGREES IN WRITING
WITH THE COMPANY TO BE SUBJECT TO SUCH TRANSFER PROVISIONS.

 

     

     

    

 

SECURITIES EVIDENCED BY THIS CERTIFICATE
AND CLASS A ORDINARY SHARES OF THE COMPANY ISSUED UPON EXERCISE OF SUCH SECURITIES SHALL BE ENTITLED TO REGISTRATION RIGHTS UNDER
A REGISTRATION RIGHTS AGREEMENT TO BE EXECUTED BY THE COMPANY.

 

EXHIBIT D

 

LEGEND FOR FORWARD PURCHASE WARRANTS

 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED, SOLD,
TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND ANY APPLICABLE STATE SECURITIES
LAWS OR AN EXEMPTION FROM REGISTRATION IS AVAILABLE. IN ADDITION, SUBJECT TO ANY ADDITIONAL LIMITATIONS ON TRANSFER DESCRIBED IN
THE FORWARD PURCHASE AGREEMENT BY AND AMONG MEDICUS SCIENCES ACQUISITION CORP. (THE “COMPANY”), ALTIUM
MSAC, LLC, AND STRUCTURE ALPHA LLC, THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD OR TRANSFERRED PRIOR TO THE
DATE UPON WHICH THE COMPANY COMPLETES ITS INITIAL BUSINESS COMBINATION (AS DEFINED IN SECTION 3 OF THE WARRANT AGREEMENT REFERRED
TO HEREIN) EXCEPT TO A PERMITTED TRANSFEREE (AS DEFINED IN SECTION 2 OF THE WARRANT AGREEMENT) WHO AGREES IN WRITING WITH THE COMPANY
TO BE SUBJECT TO SUCH TRANSFER PROVISIONS.

 

SECURITIES EVIDENCED BY THIS CERTIFICATE
AND CLASS A ORDINARY SHARES OF THE COMPANY ISSUED UPON EXERCISE OF SUCH SECURITIES SHALL BE ENTITLED TO REGISTRATION RIGHTS UNDER
THE REGISTRATION RIGHTS AGREEMENT EXECUTED BY THE COMPANY.Exhibit 4.2

 

CONTINGENT RIGHTS AGREEMENT

 

This Contingent Rights
Agreement (this “Agreement”) is made as of February 15, 2021 between Medicus Sciences Acquisition Corp., a Cayman Islands
exempted company (the “Company”), and Continental Stock Transfer & Trust Company, a New York limited purpose
trust company, with offices at 1 State Street, New York, New York 10004 (the “Rights Agent”).

 

WHEREAS, the Company
has agreed to issue and sell to Maxim Group LLC (the “Representative”), as representative of the several underwriters,
an aggregate of 8,000,000 units (the “Units”) (or 9,200,000 Units assuming full exercise of the underwriters’
over-allotment option) (the “Public Offering”), each unit comprised of one Class A ordinary share of the Company,
par value $.0001 per share (the “Ordinary Shares”), one-ninth of one redeemable warrant to purchase one Ordinary Share
(the “Detachable Warrants) and a contingent right (a “Contingent Right”) to receive at least two-ninths of one
redeemable warrant (the “Distributable Warrants” and, together with the Detachable Warrants, the “Warrants”)
upon the happening of the triggering event described herein, and in connection therewith, will deliver up to an aggregate of 9,200,000
Contingent Rights upon consummation of such public offering, of which 1,200,000 are attributable to the over-allotment option;

  

WHEREAS, the Warrants
are governed by that certain Warrant Agreement, dated as of the date hereof (the “Warrant Agreement”), by and between
the Company and Continental Stock Transfer & Trust Company as warrant agent;

 

WHEREAS, the Company
has filed with the Securities and Exchange Commission (the “SEC”) a Registration Statement on Form S-1, File No. 333-251674,
for the registration, under the Securities Act of 1933, as amended (“Act”) of the Units, the Ordinary Shares, the Warrants
and the Contingent Rights;

 

WHEREAS, the Company
desires to provide for the form and provisions of the Contingent Rights, the terms upon which they shall be distributed, and the
respective rights, limitation of rights, and immunities of the Company, the Rights Agent, and the holders of the Contingent Rights;
and

 

WHEREAS, all acts and
things have been done and performed which are necessary to make the Contingent Rights, when executed on behalf of the Company and
countersigned by or on behalf of the Rights Agent, as provided herein, the valid, binding and legal obligations of the Company,
and to authorize the execution and delivery of this Agreement.

 

NOW, THEREFORE, in
consideration of the mutual agreements herein contained, the parties hereto agree as follows:

 

	1.	Appointment of Rights Agent. The Company hereby appoints the Rights Agent to act as agent for the Company for the Contingent Rights, and the Rights Agent hereby accepts such appointment and agrees to act in accordance with the terms and conditions set forth in this Agreement.

 

	2.	Contingent Rights.

 

	 	2.1.	Form of Contingent Right. The Contingent Rights shall be considered to be attached to the Ordinary Shares, with each single Contingent Right attached to one Ordinary Share, and each single Ordinary Share having attached to it one Contingent Right. The Contingent Rights are not separately transferable, assignable or salable, and will not be evidenced by any form of certificate or instrument.

 

	 	2.2	No Rights as Shareholder. A Contingent Right does not entitle the holder thereof to any of the rights of a holder of Ordinary Shares of the Company, including, without limitation, the rights to receive dividends or other distributions, exercise any preemptive rights, vote, consent, receive notice as shareholders in respect of meetings of shareholders or the election of directors of the Company, or any other matter.

 

     

     

    

 

	3.	Terms of Contingent Rights.

 

	 	3.1.	Contingent Rights. Each Contingent Right shall entitle the holder thereof to receive at least two-ninths of one Distributable Warrant at the Distribution Time (as defined in the Warrant Agreement), as follows: (i) to the extent that no public holders of Ordinary Shares (such holders, “Public Shareholders”) redeem their Ordinary Shares in connection with the Business Combination (as defined in the Warrant Agreement) each Public Shareholder will receive two-ninths of a Distributable Warrant, and (ii) to the extent that any Public Shareholders redeem any of their Ordinary Shares in connection with the Business Combination, then (A) two-ninths  of a Distributable Warrant will be issued for each Ordinary Share that was not redeemed (the “remaining public shares”), and (B) the aggregate amount of 1,777,778 Distributable Warrants less the number of warrants  issued pursuant to the foregoing clause (A) will be issued on a pro rata basis to the holders of the remaining public shares based on their percentage of Ordinary Shares held after redemptions. To the extent that a Public Shareholder redeems any of their Ordinary Shares in connection with the Business Combination, that Public Shareholder will receive no portion of any Distributable Warrant per Ordinary Share redeemed. No additional consideration shall be paid by a holder of Contingent Rights in order to receive his, her or its Distributable Warrants at the Distribution Time. In no event will the Company be required to net cash settle any Contingent Rights or distribute any fractional Distributable Warrants.

 

	 	3.2.	Distribution Time. At the Distribution Time, the Company will effect a distribution of a number of Distributable Warrants pursuant to the terms and conditions of the Warrant Agreement.

 

	 	3.3.	Duration of Contingent Rights. If a holder of an Ordinary Share submits that Ordinary Share for redemption in accordance with the Company’s Amended and Restated Memorandum and Articles of Association, the Contingent Right attached to such Ordinary Share shall expire and shall be worthless. 

 

	4.	Provisions Concerning the Rights Agent and Other Matters.

 

	 	4.1.	Payment of Taxes. The Company will from time to time promptly pay all taxes and charges that may be imposed upon the Company or the Rights Agent in respect of the Contingent Rights.

 

	 	4.2.	Resignation, Consolidation, or Merger of Rights Agent.

 

	 	4.2.1.	Appointment of Successor Rights Agent. The Rights Agent, or any successor to it hereafter appointed, may resign its duties and be discharged from all further duties and liabilities hereunder after giving sixty (60) days’ notice in writing to the Company. If the office of the Rights Agent becomes vacant by resignation or incapacity to act or otherwise, the Company shall appoint in writing a successor Rights Agent in place of the Rights Agent. If the Company shall fail to make such appointment within a period of 30 days after it has been notified in writing of such resignation or incapacity by the Rights Agent or by the holder of the Contingent Right, then the holder of any Contingent Right may apply to the Supreme Court of the State of New York for the County of New York for the appointment of a successor Rights Agent at the Company’s cost. Any successor Rights Agent, whether appointed by the Company or by such court, shall be a corporation organized and existing under the laws of the State of New York, in good standing and having its principal office in the Borough of Manhattan, City and State of New York, and authorized under such laws to exercise corporate trust powers and subject to supervision or examination by federal or state authority. After appointment, any successor Rights Agent shall be vested with all the authority, powers, rights, immunities, duties, and obligations of its predecessor Rights Agent with like effect as if originally named as Rights Agent hereunder, without any further act or deed; but if for any reason it becomes necessary or appropriate, the predecessor Rights Agent shall execute and deliver, at the expense of the Company, an instrument transferring to such successor Rights Agent all the authority, powers, and rights of such predecessor Rights Agent hereunder; and upon request of any successor Rights Agent the Company shall make, execute, acknowledge, and deliver any and all instruments in writing for more fully and effectually vesting in and confirming to such successor Rights Agent all such authority, powers, rights, immunities, duties, and obligations.

 

	 	4.2.2.	Notice of Successor Rights Agent. In the event a successor Rights Agent shall be appointed, the Company shall give notice thereof to the predecessor Rights Agent and the transfer agent for the Warrants not later than the effective date of any such appointment.

 

     

     

    

 

	 	4.2.3.	Merger or Consolidation of Rights Agent. Any corporation into which the Rights Agent may be merged or with which it may be consolidated or any corporation resulting from any merger or consolidation to which the Rights Agent shall be a party shall be the successor Rights Agent under this Agreement without any further act.

 

	 	4.3.	Fees and Expenses of Rights Agent.

 

	 	4.3.1.	Remuneration. The Company agrees to pay the Rights Agent reasonable remuneration for its services as s Rights Agent hereunder and will reimburse the Rights Agent upon demand for all expenditures that the Rights Agent may reasonably incur in the execution of its duties hereunder.

 

	 	4.3.2.	Further Assurances. The Company agrees to perform, execute, acknowledge, and deliver or cause to be performed, executed, acknowledged, and delivered all such further and other acts, instruments, and assurances as may reasonably be required by the Rights Agent for the carrying out or performing of the provisions of this Agreement.

 

	 	4.4.	Liability of Rights Agent.

 

	 	4.4.1.	Reliance on Company Statement. Whenever in the performance of its duties under this Agreement, the Rights Agent shall deem it necessary or desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder, such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed to be conclusively proved and established by a statement signed by the Chief Executive Officer or Chief Financial Officer and delivered to the Rights Agent. The Rights Agent may rely upon such statement for any action taken or suffered in good faith by it pursuant to the provisions of this Agreement.

 

	 	4.4.2.	Indemnity. The Rights Agent shall be liable hereunder only for its own gross negligence, willful misconduct or bad faith. The Company agrees to indemnify the Rights Agent and save it harmless against any and all liabilities, including judgments, costs and reasonable counsel fees, for anything done or omitted by the Rights Agent in the execution of this Agreement except as a result of the Rights Agent’s gross negligence, willful misconduct, or bad faith.

  

	 	4.4.3.	Exclusions. The Rights Agent shall have no responsibility with respect to the validity of this Agreement or with respect to the validity of any Contingent Right; nor shall it be responsible for any breach by the Company of any covenant or condition contained in this Agreement or in any Contingent Right; nor shall it by any act hereunder be deemed to make any representation or warranty as to the authorization any Distributable Warrants to be distributed pursuant to this Agreement or any Contingent Right or as to whether any Warrant will, when distributed, be an enforceable obligation of the Company.

 

	 	4.5.	Acceptance of Agency. The Rights Agent hereby accepts the agency established by this Agreement and agrees to act upon the terms and conditions herein set forth.

 

	 	4.6.	Waiver. The Rights Agent hereby waives any right of set-off or any other right, title, interest or claim of any kind (“Claim”) in, or to any distribution of, the Trust Account (as defined in that certain Investment Management Trust Agreement, dated as of the date hereof, by and between the Company and the Rights Agent as trustee thereunder) and hereby agrees not to seek recourse, reimbursement, payment or satisfaction for any Claim against the Trust Account for any reason whatsoever.

 

	5.	Miscellaneous Provisions.

 

	 	5.1.	Successors. All the covenants and provisions of this Agreement by or for the benefit of the Company or the Rights Agent shall bind and inure to the benefit of their respective successors and assigns.

 

     

     

    

 

	 	5.2.	Notices. Any notice, statement or demand authorized by this Agreement to be given or made by the Rights Agent or by the holder of any Contingent Right to or on the Company shall be sufficiently given when so delivered if by hand or overnight delivery or if sent by certified mail or private courier service within five days after deposit of such notice, postage prepaid, addressed (until another address is filed in writing by the Company with the Rights Agent), as follows:

 

Medicus Sciences Acquisition
Corp.

152 West 57th Street, Floor 20

New York, New York 10019

Attn: Mark Gottlieb

 

Any notice, statement or demand
authorized by this Agreement to be given or made by the holder of any Contingent Right or by the Company to or on the Rights Agent
shall be sufficiently given when so delivered if by hand or overnight delivery or if sent by certified mail or private courier
service within five days after deposit of such notice, postage prepaid, addressed (until another address is filed in writing by
the Rights Agent with the Company), as follows:

 

Continental Stock Transfer &
Trust Company

1 State Street

New York, NY 10004

Attn: Fran Wolf

Email: fwolf@continentalstock.com

 

with a copy to:

Ellenoff Grossman &
Schole, LLP

1345 Avenue of the Americas

New York, NY 10105

Attn: Barry I. Grossman, Esq.

Email: bigrossman@egsllp.com

 

and

 

Loeb & Loeb LLP

345 Park Avenue

New York, NY 10154

Attn: Giovanni Caruso, Esq.

Email: gcaruso@loeb.com

 

and

 

Maxim Group LLC

405 Lexington Ave., 2nd Floor

New York, NY 10174

Attn: Clifford A. Teller, Executive
Managing Director, Investment Banking

Email: cteller@maximgrp.com

 

	 	5.3.	Applicable
    Law. The validity, interpretation, and performance of this Agreement and of the Contingent Rights shall be governed in
    all respects by the laws of the State of New York, without giving effect to conflicts of law principles that would result in
    the application of the substantive laws of another jurisdiction. The Company hereby agrees that any action, proceeding or
    claim against it arising out of or relating in any way to this Agreement shall be brought and enforced in the courts of the
    State of New York or the United States District Court for the Southern District of New York, and irrevocably submits to such
    jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction
    and that such courts represent an inconvenient forum. Any such process or summons to be served upon the Company may be served by transmitting a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in Section 5.2 hereof. Such mailing shall be deemed personal service and shall be legal and binding upon the Company in any action, proceeding or claim. 

 

     

     

    

 

	 	5.4.	Persons Having Rights under this Agreement. Nothing in this Agreement expressed and nothing that may be implied from any of the provisions hereof is intended, or shall be construed, to confer upon, or give to, any person or corporation other than the parties hereto and the holders of the Contingent Rights, any right, remedy, or claim under or by reason of this Agreement or of any covenant, condition, stipulation, promise, or agreement hereof. The Representative shall be deemed to be a third-party beneficiary of this Agreement with respect to Sections 3.1, 5.2 and 5.8 hereof. All covenants, conditions, stipulations, promises, and agreements contained in this Agreement shall be for the sole and exclusive benefit of the parties hereto (and the Representative with respect to Sections 3.1, 5.2 and 5.8 hereof) and their successors and assigns and of the holders of the Contingent Rights.

 

	 	5.5.	Examination of this Agreement. A copy of this Agreement shall be available at all reasonable times at the office of the Rights Agent in the County of New York, State of New York, for inspection by the holder of any Contingent Right.

 

	 	5.6.	Counterparts. This Agreement may be executed in any number of original or facsimile counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.
	 	 	 
	 	5.7.	Effect of Headings. The Section headings herein are for convenience only and are not part of this Agreement and shall not affect the interpretation thereof.

 

	 	5.8.	Amendments. This Agreement may be amended by the parties hereto without the consent of any holder of any Contingent Right for the purpose of curing any ambiguity, or of curing, correcting or supplementing any defective provision contained herein or adding or changing any other provisions with respect to matters or questions arising under this Agreement as the parties may deem necessary or desirable; provided, however, that any amendment that will adversely affect the interests of holders of Contingent Rights shall require the consent or vote of the holders of not less than two-thirds of the then-outstanding Contingent Rights, as evidenced by their ownership of the Ordinary Shares. The provisions of this Section 5.8 may not be modified, amended or deleted without the prior written consent of the Representative.

 

	 	5.9.	Severability. This Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect the validity or enforceability of this Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable term or provision, the parties hereto intend that there shall be added as a part of this Agreement a provision as similar in terms to such invalid or unenforceable provision as may be possible and be valid and enforceable.

 

[Signature Page Follows]

 

     

     

    

 

IN WITNESS WHEREOF,
this Agreement has been duly executed by the parties hereto as of the day and year first above written.

 

	 	MEDICUS SCIENCES ACQUISITION CORP.
	 	 
	 	By:	/s/
Michael Castor
	 	 	Name: 	Michael Castor
	 	 	Title: 	Chief Executive Officer
	 	 	 
	 	CONTINENTAL STOCK TRANSFER & TRUST COMPANY
	 	 	 
	 	By:	/s/
Erika Young
	 	 	Name:	Erika Young
	 	 	Title:	Vice President

 

[Signature page to Contingent Rights
Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00321-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00321-of-00352.parquet"}]]